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Nanocarriers have become a popular platform for delivering nucleic acid for therapeutic 
and pest control methods. The peptide-based nanocarriers, branched amphiphilic peptide 
capsules (BAPCs), have shown the ability to deliver plasmid DNA in vitro and in vivo. The 
mode of administration for nucleic acid, affects the efficiency of delivery and is dependent on the 
target tissue and environment advantages. Delivering dsRNA orally in insects can provide pest 
control in the field with minimal to no effect on surrounding species. However, this delivery 
method has proven to be highly variable. BAPCs facilitate the uptake of dsRNA in Tribolium 
castaneum when administered orally through their diet. The gene transcripts tested, BiP and 
Armet, are involved in the unfolded protein response (UPR) and successful knockdown results in 
lethality. Complexes of dsRNA-BAPCs were shown to cross the gut epithelium and enter the 
hemolymph, and further visualized in the midgut epithelial cells, fat bodies, and Malpighian 
tubules.  
Transdermal delivery of nucleic acids and compounds is challenging due to the layers of 
protective barriers of the skin. Magnetic nanobeads surrounded by a bilayer of branched 
amphiphilic peptides (BAP-MNBs) were tested for transdermal delivery in mice tails with 
various skin contact times (1 min, 5 min, 15 min, and 30 min) and post exposure incubation 
times (1 h, 8 h, and 24 h). BAP-MNBs were extracted from tissues using magnetic separation to 
look at biodistribution as a pilot study. BAP-MNBs suggest a preference for entering through the 
follicular pathway and accumulate in the spleen, indicating potential for transdermal delivery of 
DNA vaccines. 
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Chapter 1 - Nanocarriers 
In the past two decades nanocarriers have shown tremendous advances in 
nanotechnology and medical applications [1]. Nanocarriers have been explored extensively in 
research and in clinical settings for drug delivery, gene therapy, vaccinations, regenerative 
medicine, tissue engineering, cancer therapy, disease diagnosis, and molecular imaging [2, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 13].  
When designing nanoparticles for the delivery of low molecular weight drugs or nucleic 
acids the surface properties, biodistribution, and toxicity are important characteristics that need 
to be addressed [25, 26, 27, 28, 29]. The higher surface area to volume ratio provided by 
nanocarriers improves the pharmacokinetics and biodistribution, which in turn minimizes 
toxicity [30, 31, 32, 33]. Nanocarriers with extended blood circulation times, targeted delivery, 
and endosomal escape, have proven to be especially efficient in delivery and are aspects that are 
highly sought after [49, 50, 51, 52, 53, 54, 55]. In addition to these attributes, an ideal delivery 
system would be able to hold a high volume of payload and have affordable and easy 
producibility [37, 38, 39, 40, 41, 42].  
Gene therapy utilizes exogenous nucleic acid to influence gene expression in living 
organisms to treat or prevent diseases [15, 16]. Nucleic acids (DNA, RNA, and oligonucleotides) 
have great therapeutic potential, but their large molecular weight and anionic nature prevent 
them from crossing the negatively charged plasma membrane and reaching their targets in the 
cytoplasm or nucleus. Viral vectors such as adenoviruses, lentiviruses, and adeno-associated 
viruses, were the first form of gene delivery to overcome biological barriers and advanced gene-
delivery technology [14, 15, 16, 17, 18, 19]. However, they have limited load packing capacities 
and complicated production processes with high production costs [22, 23, 24]. The cytotoxicity, 
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insertional mutagenesis, and lethal immune responses of viral-associated gene delivery, which 
have yet to be resolved, have prompted the interest in less pathogenic/immunogenic options [14]. 
Non-viral vectors have the potential to address many of these shortcomings.  
 
 Inorganic Nanoparticles 
Gold nanoparticles (AuNPs) possess several characteristics which make them useful for 
drug or gene delivery, diagnostics, and therapeutic applications. They are easy to synthesize, 
have shown excellent biocompatibility, have a well-defined surface chemistry for easy 
functionalization, can be used for imaging due to their light scattering properties and tumor 
ablation based on their photothermal ability to absorb light, and have a unique surface plasmon 
resonance which can be exploited to facilitate on-demand release [24, 56, 57, 58, 59, 60]. Many 
of these properties can be tuned and optimized based on size, shape, structure, and composition 
of AuNPs. Plasmonic nanoparticles, which are based on gold or silver cores, are defined as 
nanoparticles which display localized surface plasmon resonance bands in the ultra violet-
visible-near infrared range, that are highly sensitive to subtle changes in the physiochemical 
environment [61]. Listeria monocytogenes have been detected by aggregation with 
functionalized AuNPs, based on the surface plasmon resonance-based color shift when 
aggregated with the bacteria [61]. AuNPs have also been shown to conjugate with nucleic acid 
through surface functionalization with positively charged molecules such as amino acids, 
cationic peptides, and tertiary amine-containing molecules, or by directly binding to the AuNPs 
unfunctionalized surface using gold-thiol chemistry [62, 63]. Both forms of functionalized or 
non-functionalized AuNP-DNA conjugates were shown to be effective in gene delivery [24]. 
While no AuNPs have been clinically approved, a handful which utilize light absorbing 
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properties are being investigated for use against solid tumors and acne. One example is 
AuroLase®. These silica-gold nanoshells, are coated with polyethylene glycol (PEG) and are 
designed to thermally ablate solid tumors post near infrared (NIR) activation [64, 65, 66]. This is 
achieved by inducing photothermal cell death in vitro and by increasing solid tumor tissue 
temperatures high enough to induce irreversible thermal damage in vivo [67, 68, 69]. Another 
AuNP being investigated, Sebashells, use a similar design of silica-gold nanoshells coated with 
PEG to absorb NIR and disrupt overactive sebaceous glands for acne treatment [70]. While 
AuNPs have unique advantages and uses, optimizing the surface and physical properties of 
AuNPs to ensure maximum functionality has been challenging [61, 72]. Key aspects of AuNPs 
that still need to be systematically investigated include the biological fate, long-term 
biocompatibility, cellular interactions, biodistribution, and clearance [56, 192, 16, 73].  
Magnetic nanoparticles (MNPs), which are often iron oxide nanoparticles (IONPs), have 
many uses related and unrelated to biomedicine and biotechnology, ranging from audio speakers 
and magnetic data storage to magnetic resonance imaging (MRI) and bioseparation [24, 74, 75, 
76, 77]. MNPs are most often used as contrast agents for non-invasive diagnostic imaging in 
MRI and cell imaging in transmission electron microscopy (TEM) [78, 79, 80]. Once the surface 
of MNPs are functionalized and coupled with DNA, proteins, peptides, or antibodies they have 
additional uses for drug and gene delivery, anemia treatment, tissue engineering, magnetic 
targeting, and thermal ablation of tumors [56, 71, 24, 81, 82, 83, 132, 85]. IONPs have been 
tested in clinics more than any other inorganic nanoparticle, yet a majority of the approved 
IONPs have since been discontinued without specifying any scientific reasons [56]. Many 
clinically relevant studies currently being conducted are focused on Ferumoxytol to treat iron 
deficiency in adults with chronic kidney disease intravenously where iron becomes available 
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upon degradation [86, 87]. Clinical studies of IONPs have shown that large safety concerns still 
need to be addressed, applications are limited by low doses, and many side effects have been 
reported [56, 88, 89, 90].  
Silica Nanoparticles (Silica NPs) are often used in conjunction with other nanoparticles 
(NPS) due to their favorable biodegradability and low toxicity [91, 92]. Depending on the 
biological application of interest, one can precisely tune the size, shape, porosity, and surface 
modifications of silica NPs, which all independently influence circulation time, targeting, drug 
loading/release, and cellular internalization [93, 94, 95, 96, 97, 98, 99, 100]. Due to the high 
porosity, there is a large surface area that can be used to store and release a variety of drugs, 
hydrophilic or hydrophobic. Hollow silica spheres with ordered pore structures (2.5 or 1.8nm) 
have been used as a drug delivery and gene transfection system [72]. Sumistha Das et al. 
reported that amine functionalized silica NPs were ineffective for oral dsRNA delivery to 
mosquitos without further extensive modifications [104]. Cornell-Dots (C-Dots), which are 
hybrid silica NPs with a near infrared fluorophore, PEG coating for immune system avoidance, 
and a 124I radiolabeled cRGDY targeting peptide for PET imaging and improved targeting and 
accumulation, are in clinical trials for imaging and diagnostics of tumors (ClinicalTrials.gov 
identifiers NCT01266096 and NCT02106598) [101]. C-Dots have no reported toxicity or 
adverse effects, are stable in vivo, have consistent pharmacokinetic properties, and are capable of 
imaging metastatic lesions [101, 102]. Despite these successes, for silica NPs to progress, long 
term in vivo fate and optimal size/shape/porosity still need to be determined.  
Quantum Dots (QDs) are inorganic semiconductor nanocrystals 2-8 nm in size, which 
can be observed with confocal microscopy, total internal reflection microscopy, or basic wide-
field epifluorescence microscopy [71, 105]. QDs are brighter than fluorescent dyes, resist to 
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photobleaching, and have multicolor emission, making them favorable fluorescent probes [103]. 
Additionally, QDs can be covalently linked to biorecognition molecules making them useful for 
gene delivery, fluorescent labeling of cellular proteins, cell tracking, pathogen and toxin 
detection, and in vivo animal imaging [71].  
Carbon Nanotubules (CNTs) were the first inorganic nanomaterial to show that 
biocompatibility may be determined by surface functionalization rather than size, shape, or 
material, and have been widely explored since they were first described in 1991 [24, 106]. CNTs 
were found to have low toxicity and were easily translocated across the cell membrane but had 
limited biocompatibility alone [107, 108]. Water-soluble functionalized CNTs however, helped 
increase biocompatibility and were shown to be rapidly cleared from systemic blood circulation 
in mice [109]. Due to their hollow cores, CNTs can be used to carry a wide variety of drugs or 
nucleic acid based on surface modifications to accommodate the load [110, 111]. Gene 
expression for CNT-DNA conjugates was shown to be 10x higher than DNA alone, likely due to 
their ability to penetrate the cell like a nano-needle, bypassing the endocytosis pathway for 
delivery [24, 106, 112]. However, CNTs have a wide size distribution, which can influence 
systemic biodistribution, target ability, and drug release [72].  
While inorganic nanoparticles offer unique diagnostic and therapeutic opportunities, they 
often cannot be used without organic modifications, and have not been approved for any 
drug/gene delivery applications [72]. 
 
 Organic Nanoparticles 
Organic nanoparticles are promising non-viral vectors due to their improved circulation 
and reduced toxicity making them ideal for loading genes for chemotherapy [113]. They have 
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higher biocompatibility and biodegradability compared to inorganic nanoparticles and can be 
based on a large variety of compounds including lipids, polymers, and peptides [45, 46, 47].  
 
 Lipid-Based Nanoparticles 
Lipids are hydrophobic or amphiphilic in nature. Amphiphilic lipids have a hydrophilic 
region as well as a hydrophobic region, such as a phospholipid. When these lipids are placed in 
an aqueous solution, the hydrophobic regions are drawn towards each other and often form 
micelles, where the core is all hydrophobic tails facing each other, or more likely liposomes, 
where the hydrophobic tails face each other forming a bilayer with an aqueous core and 
hydrophilic heads also interacting with the aqueous solution surrounding the liposome. These 
structures were first described by Alec Bangham and his coworkers in 1964 and have since been 
researched and used extensively [114, 115]. The lipids used to form liposomes can be natural or 
synthetic and can determine the physiochemical and colloidal characteristics such as size, 
composition, loading efficiency, stability, and biological interaction [116, 117]. Cationic lipids 
are preferred for cellular uptake due to the natural electrostatic attraction to the negative charge 
on the cellular membrane. Charge neutral lipids, also known as helper lipids such as cholesterol, 
are integrated with cationic lipids to help form and stabilize the bilayer [15, 20, 21]. Liposomes 
are one of the most clinically established nanocarrier systems used to deliver drugs, nucleic acid, 
and imaging agents [1]. They have been used in ocular and pulmonary applications as well as 
cancer and gene therapy [116, 118, 130, 119].  
New generation liposomes have altered characteristics to improve tissue targeting over 
standard liposomes. These include liposomes with modified lipid composition such as 
archaeosomes, containing lipids with diether linkages, and ethosomes, which have a high 
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concentration of alcohol functionalities [116, 120, 121]. Others have surface modifications such 
as virosomes which have fusogenic viral envelope proteins on their surface and cryptosomes 
which have a PEG coating [116, 122, 123]. Additional new generation liposomes include 
niosomes with a non-ionic surface, transferosomes for transdermal delivery, novasomes with 2-7 
bilayer shells, emulsomes which have a solid fat core surrounded by bilayer, and genosomes for 
gene or DNA delivery [116, 124, 125, 126, 127, 128].  
While liposomes have been the focus of most lipid-based nanocarriers, other lipid-based 
carriers show promising delivery capabilities. Cationic lipids interact with the negatively charged 
siRNA through electrostatic interactions and form lipoplexes [129]. These lipoplexes form multi-
layer sheets where the negatively charged siRNA is layered between the positively charged 
layers  of cationic lipids. These lipoplex layers are approximately 3.7 nm thick, with a 2 nm gap 
between each layer where the siRNA is situated. Stable nucleic acid-lipid particles were studied 
to combat the Zaire strain of the Ebola virus in guinea pigs, the hepatitis B virus in mice, and 
dyslipidemia in monkeys [49, 25, 34, 35, 131, 36]. 
Despite the success of liposomes for delivery, there remains some concerns for 
therapeutic use. Some cationic lipids have shown toxicity in vitro and in vivo, which PEGylation 
can mediate, and some synthetic lipids have the ability to produce off target effects [133, 134]. 
Additionally, studies have shown low drug loading efficiency and poor stability of liposomes 
[135]. While these are characteristics that can be optimized with further research, there have also 
been reports of variation between batches made, which creates a large roadblock for scale-up 
production in the future [49].  
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 Polymer-Based Nanoparticles 
Polymer based nanoparticles are the simplest form of soft-material gene and drug 
delivery systems with low immunogenicity, absence of mutagenesis, low production costs, and 
versatility in structure and chemical makeup [136, 137, 138, 139, 14]. They are made up of 
repeating polymer segments referred to as blocks. Natural and synthetic polymers are very 
diverse and can be linear or branched. When designing the polymers composition, solubility, 
crystallinity, molecular weight, backbone stability, hydrophobicity, and polydispersity are 
carefully weighed depending on the target environment as well as the cargo being carried, based 
on its molecular weight and net charge [140, 139, 141]. The block copolymer chemistry used to 
create polymersomes can be tuned to the needs of the target and cargo based on the block used. 
Amphiphilic block copolymers can self-assemble into micelles (spherical, prolate, or oblate) or 
vesicles (polymersomes) depending on the ratio of hydrophilic to hydrophobic block volumes 
[142]. Micelles form from a single layer of amphiphilic copolymers where the hydrophobic 
blocks are all at the core and the hydrophilic blocks interact with the aqueous solvent, much like 
a detergent. Polymersomes on the other hand form a bilayer of amphiphilic copolymers with the 
hydrophobic blocks interacting with each other and forming a shell with the hydrophilic blocks 
interacting with the aqueous solution and simultaneously creating an aqueous core. Compared to 
polymersomes, micellular structures can only encapsulate hydrophobic components in the core in 
aqueous solutions. Polymersomes can encapsulate hydrophilic components in the aqueous core 
and hydrophobic components in the thick lamellar membranes simultaneously [143].  
Some of the first copolymers made were not fully biocompatible and were not 
biodegradable. Later polymer vesicles showed the ability to escape the endosome within minutes 
of endocytosis, due to the reductive environment, by the proposed proton-sponge-effect [142]. 
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Compounds that have high pH buffering capacity or large positive charges within the endosome 
causes a diffusion of chloride ions into the endosome to neutralize the positive charge followed 
by an influx of water, causing large osmotic pressure and eventually bursting the endosome, 
releasing the contents [15, 144].  
Common polymer blocks include Polyethylene glycol (PEG), polyethyleneimine (PEI), 
and cyclodextrins (CDs). PEG is commonly used in polymersomes and in conjunction with other 
nanocarriers to shield the nanocomplex from interaction with the extracellular environment and 
prolong its circulatory half-life, often referred to as “stealth-ing” [147].  Polyethyleneimine (PEI) 
is a broadly investigated delivery carrier that can condense DNA into polyplexes and can escape 
endosomes [25, 145]. Unmodified PEI is cytotoxic and have low transfection rates due to the 
high positive charge. Combining with disulfide modified hyaluronic acid (DNA-PEI-HA-SS-
COOH) lowers the toxicity. Cyclodextrins (CDs) are natural cyclic polymers composed of alpha-
1,4-D-glucose or amylose, with low immunogenicity, that can interact with nucleic acids [15, 
146]. CDs have been shown to inhibit tumor growth of mouse metastatic Ewing’s sarcoma and 
can safely be administered to non-human primates [25, 148]. One way to make fully-
biodegradable vesicles is to use polypeptides. Sun et al. created poly(L-Lysine)-block-poly(L-
phenylalanine) (PLL-b-PPA) which spontaneously assemble into giant vesicles in aqueous 
solutions [149].  
 
 Peptide-Based Nanoparticles 
Peptides are an attractive material for nanosized delivery because they can be made of 
naturally occurring amino acids, serve as biologically active compounds or building blocks, and 
have sequence and function diversity [2, 37]. Each combination of amino acids will present their 
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own unique 3D structures, electric charges, and hydrophobicity, allowing for endless possibilities 
for cargo and delivery needs [37]. Additionally, peptide delivery systems have high drug loading 
capacity, low drug leakage, are biodegradable, and have high permeability to cellular 
membranes, giving them large advantages over liposomes and other nanoparticles [2, 150, 151]. 
As of 2015 more than 60 peptide therapeutics have been approved by the Food and Drug 
Administration, with many more being researched and in clinical trials [43].  
Cell Penetrating Peptides (CPPs) are peptides composed of 10 to 40 amino acids, that are 
naturally capable of penetrating the cellular membrane and translocating into the cytoplasm [44, 
45, 48]. The small size and low immunogenicity of peptides compared to proteins and antibodies 
allows them to penetrate tissues and solid tumors at a higher rate [43, 152]. CPPs are often 
attached to cargo intended for delivery, such as nucleic acids and small molecules through 
covalent or non-covalent interactions [44]. CPP conjugates have been shown to be sensitive to 
serum, creating mixed results in vivo [45]. While there has been some success using CPPs as 
nanocarrier, the cationic peptides can modify the cargo they are carrying potentially biologically 
inactivating the cargo, aggregation is likely to occur, and consistency of conjugation with nucleic 
acid has been an issue [44].  
Another peptide-based delivery system with strong potential is self-assembling peptide 
nanomaterials. Most self-assembled molecules are formed based on weak non-covalent 
interactions between monomers [153]. These weak interactions can include electrostatic, 
hydrogen bonds, hydrophobic, and Van der Waals forces. Self-assembled structures have 
numerous weak interactions between many monomers, thereby greatly increasing stability. 
Peptides can be formulated to have amphiphilic properties to promote self-assembly into various 
structures such as nanotubules, nanovesicles, and micelles in a given environment [48]. Cyclic 
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peptides, made from alternating D- and L-amino acids, often self-assemble into nanotubules by 
stacking on top of each other [154]. Peptides that form these nanotubule or nanofibrous 
structures could be used to mimic the natural extracellular matrix for tissue engineering, as well 
as deliver localized drugs. Other self-assembled peptide carriers have shown successful delivery 
to the central nervous system, cardiovascular system, inside the eyes, into bones, and able to 
carry anticancer drugs [2, 155, 156, 157, 158, 159].  
 
 Branched Amphiphilic Peptide Capsules 
A newer class of self-assembling peptide-based nanocapsules, Branched Amphiphilic 
Peptide Capsules, were first described by Gudlur et al. [160]. These capsules are composed of 
two peptides which are amphiphilic in nature with a polar oligo-lysine (K=5) head attached to 
branched hydrophobic segments, composed of nine or five amino acid residues, and are 
composed entirely of naturally occurring amino acids (Figure 1.1). If the peptides contain nine or 
five amino acids in the hydrophobic segments, they are referred to as h9 or h5 respectively. The 
hydrophobic segments were derived from an internal fragment of a naturally occurring human 
dihydropyridine sensitive L-type calcium channel segment CaIV3 
(DPWNVFDFLIVIGSIIDVILSE). The architecture of these peptides is similar to diacyl 
Figure 1.1 - Sequence of h9 and h5 Peptides 
Sequences of the self-assembling branched peptides h9 (top) and h5 (bottom). The peptides are N-terminal acetylated 
(Red), the branch point lysine (green) with branches coming off the α-amino group of the N-terminus and the ε-
amino group of the side chain.  
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phospholipids where the branch point lysine (highlighted in green in Figure 1.1) orients the two 
peptide segments at a ~90° angle off the α- and ε-amino groups. These peptides adopt a helical 
conformation and remain in a monomeric state in organic solvents such as 2,2,2-
Trifluoralethanol (TFE). However, once these peptides are placed in water they adopt very stable 
beta-like structures, where the hydrophobic segments drive the initial formation of a bilayer, 
water filled, spherical structures which are referred to as a branched amphiphilic peptide capsules 
(BAPCs) [160]. This initial formation, driven by hydrophobic effects and Van der Waals forces, 
is comparable to the forces that stabilize liposomes. However, BAPCs also engage in hydrogen 
bonding between adjacent beta-structures [160]. This high level of stability helps maintain the 
structural integrity at low micromolar concentrations where most phospholipid bilayers would 
disassemble. BAPCs possess many other properties similar to phospholipid vesicles such as 
fusion, solute encapsulation, and ability to be resized by  membrane extrusion through 
polycarbonate filters with defined pore sizes. Course-grained modeling further supports the 
hypothesis that these capsules form in a bilayer spherical shape like liposomes [160].  
Initial studies demonstrated that BAPCs were able to encapsulate the small water-soluble 
dye molecules 5(6)-Carboxyfluorescein, tryptophan, and Rhodamine 6G, which provided the 
platform needed to assess if these peptide assemblies could be used as delivery vehicles in vitro. 
Co-localization of entrapped 5(6)-Carboxyfluorescein and covalently attached 
Carboxytetramethylrhodamine within the cells shows that intact BAPCs were able to enter the 
cytoplasm rather than fusing with the cellular membrane and releasing the encapsulated contents 
[160].  
Seeing the potential to use BAPCs as a nanosized drug delivery system, further 
biophysical and structural studies were conducted [161]. After the h9 and h5 peptides were mixed 
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in equimolar ratios and dried as monomers, water was added to the solution for BAPC formation 
and size and  morphology were observed for varying timepoints. Within 5 min of adding water, 
clusters of nanofibrils form. At 10 min post water addition the nanofibril structures break down 
and you begin to see the first capsules appear (~20nm). After 30 min, an accumulation of 
uniform ~20-30 nm capsules are present. As the solution continues to sit at room temperature 
after an hour fusion begins to be observed via “spheres of spheres.” By 2 h post water addition, 
fusion has taken place with sizes ranging from 100 nm to more than 500 nm. After 24 h you can 
see some fusion capsules with a size close to 1 μm.  
The size of nanocapsules is crucial for efficient cell and tissue uptake. To achieve a 
uniform size of ~20-30 nm, the peptides interacted for 30 min at room temperature (25°C) and 
then placed at 4°C for 1 h to stop fusion events, then rewarmed to 25°C. BAPCs that are 
subjected to this thermal cycling, termed “locked” BAPCs, remain in uniform ~20-30 nm size 
and are unaffected by solvents, salts, chaotropes, or temperature [161].  
With the ability to prepared locked BAPCs at a fixed size, and with the success of initial 
studies, further investigation in cellular uptake and encapsulated solutes was performed. It was 
hypothesized that after BAPCs entered the cell, cellular degradation processes would eventually 
break open the BAPCs and release the encapsulated solutes. Observing co-localization of BAPCs 
and late endosomes, it appears that most BAPCs entered the cells through an endocytic pathway, 
but quickly escaped the late endosomes. The most likely mechanism for late endosomal escape is 
the proton-sponge-effect, which is commonly observed for cationic particles. Further, cells 
incubated at 37°C readily took up BAPCs while those incubated at 4°C accumulated at the cell 
surface, likely unable to pass through. This indicates the uptake mechanism is energy dependent, 
but the exact mechanism is not fully understood.  
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To study BAPC’s ability to release encapsulated solutes and small proteins, Cytochrome 
c and RNase A were encapsulated in the hydrophilic core of the BAPCs and delivered to cells. 
Both proteins are known to trigger cellular apoptosis, however no significant cellular apoptosis 
occurred as expected, while the control Pep-1 with the same proteins lead to lethal cytotoxicity. 
The BAPCs were incubated for 14 days, and still there were no results that indicated the release 
of these encapsulated proteins. Daughter cells were seen with internalized labeled BAPCs 
without cytotoxic affects as well. This surprising result indicates that BAPCs are not degraded by 
cellular machinery as originally hypothesized. This surprising characteristic altered the focus of 
using BAPCs to deliver drugs, and instead they were used for alpha-particle therapy, which holds 
potential as a therapeutic treatment for micro metastases. α-Emitting actinium-225 (225Ac), which 
has a half-life of 9.9 days, was encapsulated within BAPCs. Because the capsules are not 
degraded by cellular mechanisms, 225Ac and its daughter isotopes are confined within the capsule 
and do not freely circulate within the body causing off-target cytotoxicity. It was found that the 
radioactive materials remained encapsulated for days and even through multiple cell divisions 
[162].  
While encapsulation and subsequent release of materials is not likely for BAPCs in 
higher organisms, creating nanoparticles with nucleic acid bound to the surface emerged as 
another potential use. Often nucleic acid delivery is used for gene therapy and needs to cross the 
plasma membrane and reach targeted subcellular organelles to be effective. Macromolecules 
such as plasmid DNA (pDNA) are anionic and are not able to permeate the negatively charged 
plasma membrane. To deliver pDNA to a cell, it typically needs to be associated with a 
molecular carrier. The positive charged lysine heads of the h9 and h5 peptides on BAPCs make 
this a desirable approach.  
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Before binding nucleic acids to the BAPC surface the lab attempted to encapsulate DNA 
within the BAPC core during capsule formation, similar to the small solutes and proteins as 
previously described. However, when adding an aqueous DNA solution to dried monomeric 
peptides BAPCs were not able to form in their standard shape. At a high peptide to pDNA ratio 
long nanofibers were formed. At lower peptide to pDNA ratios the DNA and peptides seemed to 
compact into nanocondensates.  
The ratio of peptide to pDNA was determined and described as a charge ratio (N:P) 
between the number of NH3
+s (N) in the oligo lysine tails of the peptides and the number of PO4
-
s (P) in the nucleic acid, in this case this was a 4.7 kb pDNA. A N:P ratio of 65.5 here is 
referring to 50 μM peptides and 3.2x10-7 μM pDNA for a single transfection reaction of 1 mL. 
Transfection efficiency in HeLa cells with this N:P ratio was only about 2%. A high N:P ratio 
was used initially, as this was previously reported to have the highest transfection efficiencies. 
However, after exploring a range of N:P ratio and including 1 mM CaCl2, which was reported to 
improve transfection efficiency with cell penetrating peptides/DNA complexes, lower N:P ratio 
transfection rates increased 10-fold. N:P ratios of 2.6 and 10.4 showed the highest gene 
Figure 1.2 - TEM Images of DNA-BAPC Peptiplexes at Different Ratios 
(A) Nanofiber structures at charge ratio N:P = 65.5. (B) Plasmid DNA in the absence of peptide, shown to compare 
the different supramolecular structures. (C) Nanocondensate complexes formed at lower charge ratio N:P = 10.4. 
Scale bar = 200 nm. Reprinted with permission from Avila, L. Adriana et al. 2015. Branched Amphiphilic Cationic 
Oligopeptides Form Peptiplexes with DNA: A Study of Their Biophysical Properties and Transfection Efficiency. 






expression with minimal toxicity to the cell. Looking at TEM of the higher N:P ratio of 65.5, 
lower N:P ratio of 10.4, and plasmid DNA alone in Figure 1.3 shows the varied morphology, and 
likely explanation for transfection efficiency difference. It is hypothesized that at the higher N:P 
ratio the peptides coated the pDNA as shown in the left panel, creating the long fibrous 
structures, while at the lower N:P ratios the pDNA and peptides were more compacted as shown 
in the right panel. The natural structure of pDNA alone is shown for reference in the middle 
panel. Additionally, the Zeta potential of the N:P ratio of 10.4 complexes was measured as +5 
mV which is suitable to facilitate interactions with the negative cell membranes, but not high 
enough to cause cell damage [163].  
  Because the pDNA could not be encapsulated successfully and the highest 
transfection efficiency with the condensed structures only reached 20%, a different methodical 
approach was investigated. Locked BAPCs were prepared in water as normal and dried prior to 
adding pDNA. This methodology allowed for the locked BAPCs to act as nucleation centers for 
the pDNA to attract to and 
coat the surface of the 
BAPCs. Imaging in AFM 
showed single and clustered 
pDNA-BAPC nanoparticles, 
indicating there are several 
modes of associating with 
each other and likely compact 
similarly to histones. These 
structures showed higher 
Figure 1.3 - Scheme Representing DNA-BAPC Interaction at 
Different Ratios 
Left panel shows scenario in which the branched peptide sequences bridge the 
DNA at low N:P ratios allowing them to be pulled together. The right panel 
shows a hypothetical structure where the DNA is encased within a peptide 
bilayer. Lysines are represented by positive charges in the circles. Reprinted 
with permission from Avila, L. Adriana et al. 2015. Branched Amphiphilic 
Cationic Oligopeptides Form Peptiplexes with DNA: A Study of Their 
Biophysical Properties and Transfection Efficiency. Molecular 
Pharmaceutics 12 (3): 706-715. Copyright 2015 American Chemical Society.   
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transfection rates and lower cytotoxicity than the commercially available transfection reagent 
Lipofectin. Additionally, BAPCs were complexed with a larger 19.4 kb plasmid which encodes 
the entire genome for the North American type I porcine and reproductive system virus 
(PRRSV): pCMV-SD95-21-GFP. Delivery of this plasmid via BAPCs and expression resulted in 
shedding of competent RNA virus, making BAPCs a potential vaccine delivery system. 
 While many transfection reagents and nanoparticles show high gene delivery efficiency 
in vitro, most of them fail to produce the same results in vivo [263, 264, 265]. Researchers are 
continually trying to generate nano-delivery systems that can overcome the extracellular and 
intracellular obstacles for in vivo delivery. BAPCs have previously been shown to be able to 
deliver the DNA vaccine encoding the oncoprotein of type 16 human papillomavirus 
intramuscularly in mice, and delayed tumor growth at comparable rates to the HPV-16 DNA 
alone [164]. If BAPCs can deliver nucleic acid through non-injection methods, this could 
provide further applications for gene delivery, DNA vaccinations, and RNA interference with 
minimal invasion and easier administration. 
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Chapter 2 - Bioaccumulation of dsRNA delivered orally via 
BAPCs in Tribolium castaneum  
 Introduction 
Almost three decades ago, Andrew Z. Fire et al. first described the gene silencing ability 
of RNA in Caenorhabditis elegans [165]. It was later determined that the initiator of blocked 
gene expression was double stranded RNA (dsRNA) and not single-stranded antisense RNA as 
originally thought [166]. Since then the highly conserved, sequence specific, post-transcriptional 
process of RNA interference (RNAi) has been a crucial tool in reverse genetics and shows 
promise for a variety of research fields. In genomics RNAi is used to determine gene function 
and complete knockdown studies, it can be used for medicinal purposes to control cancer and 
viral diseases, and its high specificity makes it an intriguing method for biotechnology 
companies to control pests in agriculture [167, 168, 169, 170, 171, 172, 173, 174].  
RNAi can be divided into cell-autonomous and non-cell-autonomous processes. Cell-
autonomous RNAi is more commonly discussed and is limited to dsRNA introduced or 
expressed in a cell [170, 175]. Once the dsRNA is able to reach the cytoplasm, it is cleaved by 
RNase III, also known as dicer, into small interfering RNAs (siRNAs) that are 21-25 base pairs 
long at random [266, 268]. An siRNA is then incorporated into the RNA-induced silencing 
complex (RISC). Argonaute 2 within RISC unwinds the siRNA and cleaves the sense strand, 
leaving the antisense strand in complex with RISC, activating the complex [267, 268]. Active 
RISC seeks out, binds to, and cleaves mRNA within the cell complementary to the antisense 
RNA, thus preventing the translation of the subsequent protein [268, 269].  
The non-cell-autonomous RNAi processes, environmental and systemic, refer to the 
interfering effect that takes place in tissues or cells different from the location of introduced or 
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produced dsRNA. Environmental RNAi encompasses all processes in which dsRNA is taken up 
by the cell from the surrounding environment. This can include dsRNA taken up from the gut 
lumen to gut cells and soaking in a dsRNA solution [176]. When the silencing signal is 
transported from one cell to another or from one tissue type to another, this is referred to as 
systemic RNAi. Environmental RNAi can be followed by systemic RNAi and non-cell-
autonomous RNAi is always followed by cell-autonomous RNAi [170, 175].  
Sensitivity to systemic RNAi has been found to vary considerably among insect species 
and taxa [175]. Insect species unsusceptible to RNAi show temporary 60% or less knockdown of 
the target gene, while species sensitive to RNAi, such as coleopterans, show long lasting 
knockdown rates at 90% or higher with very small doses [177, 170, 175]. This variation indicates 
the systemic nature may act by different molecular mechanisms across taxa, while the cell-
autonomous RNAi pathways remains conserved among different insect species. In insect pests, 
two different uptake pathways have been described thus far: the transmembrane Sid-1 channel 
protein-mediated pathway and the endocytic pathway. The Sid-1 channel proteins, which export 
silencing RNAs to neighboring cells from the intestinal lumen, was first discovered in the 
nematode C. elegans. Since then, Sid-1-like channel proteins have been shown to be involved in 
the uptake of dsRNA in insect species such as the brown planthopper [182], the Colorado potato 
beetle [183], and the red flour beetle [184]. Other species like Drosophila melanogaster do not 
have Sid-1 like proteins and utilize pattern recognition receptors to uptake dsRNA through an 
endocytic pathway. Some species such as the Colorado potato beetle have been shown to utilizes 
both uptake methods [177].  
The most common form of administering dsRNA is through micro-injection into the 
hemolymph because of its high efficiency [178, 179, 180]. This method is tedious for many 
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insects, inefficient for large screens, and impractical pest control in the field. To effectively 
deliver dsRNA to insects in the field, it needed to be taken up autonomously, such as through 
feeding [170]. Feeding studies have shown variable success between insect species, making it 
challenging to optimize [181, 185].   
The transcripts of BiP (also known as GRP78) and Armet (also known as MANF) were 
chosen because of their role in the unfolded protein response (UPR) [194, 197]. Proteins 
intended for secretion or membrane location, fold and mature in the lumen of the ER, with the 
help of chaperones [192]. Accumulation of misfolded proteins in the endoplasmic reticulum 
(ER) causes ER stress and activates the unfolded protein response (UPR) [193]. Upon activation 
of the UPR the ER membrane expands to make room for the extra misfolded proteins and new 
protein-folding machinery are released to manage the misfolded proteins and reduce ER stress 
[192]. BiP (Binding Protein), also known as GRP78 (78-kDa glucose-regulated protein), is a 
major ER chaperone and has many roles, including control of UPR activation [194]. Under 
standard physiological conditions BiP binds to the intraluminal domains of stress sensors, 
maintaining their inactive state. As misfolded proteins accumulate in the ER, they compete with 
the stress sensors to bind with BiP. As BiP releases from the stress sensors to help manage the 
misfolded proteins as a chaperone, the sensors in turn activate the UPR [193]. It has been shown 
that low expression levels of BiP can cause severe damage to the ER and cell death [195, 196]. 
Armet (arginine-rich, mutated in early stage tumors), also known as MANF (mesencephalic 
astrocyte-derived neurotrophic factor), is suggested to promote neuron proliferation and is shown 
to be associated with the UPR, though its detailed role is still being studied [197]. HeLa cells 
treated with siRNA targeting Armet were more susceptible to ER stress-induced death [193].    
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 Materials and Methods 
 Peptide Synthesis 
The branched amphiphilic peptides bis(Ac-FLIVIGSII)-K-K4-CO-NH2 and bis(Ac-
FLIVI)-K-K4-CO-NH2 were synthesized and cleaved as previously described [160]. After 
cleavage, the peptides are washed with diethyl ether three times, dissolved in water, and 
lyophilized before storage at room temperature. The peptides were purified by reversed phase 
HPLC and characterized using matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF/TOF).    
 
 Locked BAPC Preparation 
A small amount of the peptides bis(h9) and bis(h5) were individually dissolved in 2,2,2-
Triuoroethanol (TFE) where they adopt a helical formation. Their concentrations were 
determined using molar absorptivity (ε) of phenylalanine (2 per peptide sequence) in water at 
257.5 nm, (194 cm-1M-1). The absorbances were read using CARY 50 Bio UV/Vis 
spectrophotometer (Varian Inc., Palo Alto, CA) in a 0.3 cm path length quartz cuvette (Starna 
Cells Inc., Atascadero, CA). The peptides were then mixed together at an equimolar ratio to 
achieve a 1mM final concentration. This solution was incubated at room temperature for 10 min, 
followed by solvent removal under vacuum. Once the solution was completely dried, 1 mL of 
distilled water was added drop-wise, mixed well with a pipette, and allowed to incubate at room 
temperature for 30 min to form the water-filled capsules. After this incubation period the 
solution was placed at 4°C for 1 h to prevent capsule fusion [161], then incubated for 30 min at 
room temperature again before mixing with dsRNA or drying under vacuum for long term 
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storage. This procedure of thermal shifting creates locked BAPCs 20-30 nm in diameter which 
are resistant to fusion and disassembly in the presence of organic solvents [161]. 
 
 RNA extraction and cDNA synthesis 
Seven Tribolium larvae, weighing 2 mg each, were homogenized using a polypropylene 
pestle in 1 mL of TRIZOL reagent according to the protocol supplied by the manufacturer 
(Invitrogen, CA, USA) to extract the RNA. DNA contamination was minimized in the RNA 
fraction by using a TURBO DNA-free kit, according to the protocol (Ambion, Austin, TX, 
USA). RNA (4 μg of DNA free) was reverse-transcribed into complementary DNA (cDNA) 
using the SuperScript III First Stand Synthesis System for RT-PCR (Invitrogen, CA, USA). 
 
 dsRNA synthesis 
The nucleotide sequences of target genes (TcBiP: XM_015982882.1; TcArmet: 
XM_966545.3) were obtained from the NCBI database. Gene-specific primers, including the T7 
polymerase promoter sequences at the 5’ end, were used to synthesize dsRNA from T. 
castaneum using the AmpliScribe TM T7 Flash Transcription Kit protocol (Cat. No. ASF3507, 
Epicentre Biotechnologies, USA). PCR products were separated on a 1.4% agarose gel prepared 
in 40 mM Tris-acetate (pH 8.3) and 1 mM EDTA. Ethidium bromide was added to a final 
concentration of 0.7 μg/mL before allowing the agarose to solidify. The gels were photographed 
under UV light and images were captured by gel documentation (UVP-Digital Imaging System, 
Upland, CA, USA).  
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 dsRNA fluorescent dye labeling 
Armet-dsRNA was prepared as previously described. A 5’ EndTag Nucleic Acid 
Labeling Kit (Vector Laboratories, USA) was used to incorporate a thiol functional group to the 
5’ ends of the unmodified dsRNA, according to the protocol. A thiol-reactive Atto633 maleimide 
fluorescent dye (Atto-Tec GmbH, Germany) was incorporated on the 5’ ends. Upon completion 
of purification, the concentration was determined using nano-drop (ThermoFisher Scientific, 
USA), and labeling was confirmed by fluorescent measurements.  
 
 dsRNA-BAPC Complex Preparation 
 Ten μg of dsRNA (enough for 10 insects) was added dropwise to a solution containing 
200 μL of 400 μM BAPCs for a N:P ratio of 10. This solution was mixed carefully using a 
pipette and allowed to incubate at room temperature for 10 min before adding CaCl2 (1 mM final 
concentration) and bringing the total volume to 400 μL using nuclease free water. This solution 
incubated at room temperature for 30 min before mixing it with the insect diet.  
 
 Tribolium castaneum Diet Preparation 
Media to feed 10 insects was prepared by mixing 100 mg Golden Buffalo flour 
(Heartland Mill, Inc. Marienthal, KS) with 400 μL of BAPC-dsRNA nanoparticle complexes, 
prepared as previously described. The flour and nanoparticle mixture was held under vacuum for 
approximately 15 h. When the mixture was completely dried, it was finely ground and 
distributed to a 96-well plate with 10 mg of flour-nanoparticle mixture in a well, for one larva. 
Immediately, one larva (2 mg in weight) was placed in each well containing the prepared diet. 
For the control group containing only dsRNA, 100 mg was mixed with 10 μg of dsRNA and 1 
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mM CaCl2 final concentration in 400 μL for 10 insects. Other controls included 100 mg of flour 
mixed with 400 μL of water with and without BAPCs. Insects were kept at 30°C visual 
monitoring of phenotypes and for mortality.  
 
 Insects 
Tribolium castaneum (GA-1 strain) insects were reared at 30°C on wheat flour containing 
5% brewer’s yeast under the standard conditions as previously described [199, 200]. Larvae 
selected for this study were all around 2 mg in weight indicating they were around the same 
developmental stage. 
 
 Confocal Laser Scanning Microscopy 
Images shown in Figure 2.5 were captured using a confocal LSM 700 laser-scanning 
microscope (Carl Zeiss, Gottingen, Germany) using a 639 nm laser. Magenta color was used for 
ease of visualization and does not reflect true fluorescence color of Atto633 dye. 
 
 Size and Zeta Potential of Complexes 
Size and zeta potential were measured using a Malvern ZetaSizer (2000) instrument 
(Malvern Instruments, Malvern, UK). Samples were prepared in water at 25°C with 1 µg of 
dsRNA and varying concentrations of BAPCs (10-80 µM) or with BAPCs alone (80 µM). Data 




 Fluorometric Thiol Detection 
A thiol fluorometric detection kit (Kit-0816, Creative BioMart, New York, USA) was 
used to detect free thiol based on fluorescence resulting from complexion with a non-fluorescent 
dye according to the protocol. Fifty µL of reaction mixture containing green dye and assay buffer 
was added to each well in a black 96-well plate, followed by 50 µL of dsRNA that was processed 
through the thiol addition step of the 5’ EndTag Labeling Kit (Vector Laboratories) or 
glutathione standard at various concentrations. Fluorescence was read at Ex/Em = 490/520 nm 
with a fluorescence plate reader (Varian Inc., Palo Alto, CA).   
 
 Statistical Analyses 
Statistics were performed using GraphPad Prism 8 software (GraphPad Software, La 
Jolla, CA). Statistical significance for DLS and ZP experiments was determined using ANOVA 
test followed by Bonferroni’s post-test. For survival study (Appendix A) the Log-rank (Mentel-
Cox) test was used.  
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 Results and Discussion 
As previously described, BAPCs have shown the ability to facilitate uptake of plasmid 
DNA in several cell lines as well as in mice [163]. The success of these trials indicated the 
potential of using BAPCs to deliver other types of nucleic acid such as small oligonucleotides or 
RNA. BAPCs were examined for their ability to facilitate uptake of dsRNA through diet to 
enhance transcript knockdown in Tribolium castaneum, the red flour beetle [186]. T. castaneum, 
a common pest, is also a model organism for biochemical and cell biological processes in 
humans [187, 188, 189, 190, 191]. In nature they feed on broken grain kernels, typically wheat, 
but in the lab they are fed a diet of wheat flour with 5% w/w yeast extract. The demonstrated 
high RNAi efficiency, resistance to all classes of insecticides, and published genome of T. 
castaneum make them ideal for an RNAi-based insecticide [187].  
Dynamic light scattering (DLS) and zeta potential (ZP) were evaluated for BAPCs alone 
and dsRNA-BAPC complexes of varying dsRNA to BAPC ratios. The concentration of dsRNA 
remained constant at 1 µg while the concentration of BAPCs ranged from 10 µM to 80 µM. DLS 
of unlocked dsRNA-BAPC complexes showed a range of 260-400 nm  as opposed to the BAPCs 
alone which show 100-200 nm (Figure 2.1 A). It is hypothesized that the dsRNA wraps around 
several BAPCs, forming these clusters, comparable to histone compacting (Figure 2.1 C). ZP is 
the potential difference between the surface of a solid particle and the solvent surrounding it. 
Due to the negative potential of cellular membranes, a positive ZP is favored for cellular uptake. 
A ZP above +45 mV however, can be toxic. The ZPs for the unlocked dsRNA-BAPC complexes 
ranged from 30-50 mV (Figure 2.1 B). These complexes of dsRNA with unlocked BAPCs show 
large sizes that may be harder for the cell to uptake and ZPs higher than ideal for non-toxic 
cellular uptake. BAPCs which undergo a thermal cycle to prevent fusion and maintain a diameter 
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of 20-30 nm even in the presence of salts and chaotropes, termed locked BAPCs, were also 
complexed with dsRNA and evaluated for diameter and zeta potential (Figure 2.2). The 
concentration of dsRNA remained constant at 1 µg while the concentration of BAPCs ranged 
from 10 µM to 40 µM. DLS showed a range of sizes 70-300 nm (Figure 2.2 A). The ZPs for the 
locked dsRNA-BAPCs ranged from 10-28 mV (Figure 2.2 B) indicating that cellular uptake of 
the complexes is favorable, without posing toxicity risks. The dsRNA-BAPC complexes and 
BAPCs alone were also observed using atomic force microscopy (AFM) by a previous lab 
member (Figure A.1). In those images it appears the dsRNA-BAPC complexes form compact 
clusters varying in size (70-500 nm) and morphology, agreeing with the DLS data and the 
hypothesized clustering (Figure 2.1 C). 
As evaluated by former lab members, feeding T. castaneum larvae a combination of BiP- 
and Armet-dsRNA complexed with BAPCs showed the highest lethality rate at 75% (n=30) with 
death occurring in the larval or eclosion stages (Figure A.2). Feeding adult beetles, the same 
mixture showed no death. During the molting phases the peritrophic membrane lining the midgut 
is reorganized, potentially allowing the complexes to penetrate deeper. Adult beetles no longer 
go through this phase and explains why oral delivery of BAPC-dsRNA complexes had no effect. 
To further ensure the dsRNA could cross this midgut barrier a well-studied gene, Vermillion, 
was also targeted. When the Vermillion gene is accurately targeted by RNAi, adult beetles lack 
pigmentation in their eyes. To see the expected effect when fed orally, the vermillion dsRNA 
must migrate from the gut to the hemolymph. Vermillion-dsRNA was complexed with BAPCs 
and fed to larvae as previously described. 50% (n=20) of the beetles had white eyes upon 











































































































































Figure 2.1 - Dynamic Light Scattering (DLS) and Zeta Potential (ZP) Analyses for BAPCs 
and dsRNA-BAPC Complexes (Unlocked) 
 (A) Size (z-average) and (B) zeta potential. Data are based on two independent experiments. Different formulations 
were tested keeping the amount of Armet-dsRNA constant (1 µg) and varying the unlocked BAPCs concentration. 
Differences between values were compared by one-way ANOVA using Bonferroni as post-test (N = 5). Statistical 
significance: (*) p < 0.05. Non-statistical significance (ns) was considered when p > 0.05. (C) Schematic 
representation of interaction between BAPCs and Armet-dsRNA. Image in panel C reprinted with permission from 
Avila, L. Adriana et al. 2018. Delivery of lethal dsRNAs in insect diets by branched amphiphilic peptide capsules. 




gut to the circulatory system (Hemolymph). Understanding how the dsRNA can to travel from 
the gut to the hemolymph is crucial in further understanding systemic RNAi in T. castaneum.   
To visualize the biodistribution of the dsRNA, a 5’ EndTag labeling kit from Vector Labs 
was used to create Atto633-fluorescently labeled Armet-dsRNA, via thiol-maleimide chemistry. 
Detection of accurate fluorescent labeling was difficult due to the small maximum amount of 
dsRNA able to be labeled at a time (0.6 nmols). To ensure the difficulty of detection was not due 
to malfunction of the kit itself, a thiol fluorometric detection assay was used. This assay can 
detect as little as 1 picomole of free thiol in 100 µL using a proprietary non-fluorescent dye, that 
becomes strongly fluorescent upon reacting with thiol. This assay indicated that free thiol was 
present in 1.8 µM dsRNA after the thiol addition step of the 5’ EndTag labeling kit at similar 
Figure 2.2 - Dynamic Light Scattering (DLS) and Zeta Potential (ZP) Analyses for 
BAPCs and dsRNA-BAPC Complexes (Locked) 
Dynamic Light Scattering (DLS) and Zeta Potential (ZP) analyses for different BAPCs-dsRNA 
formulations. (A) Size (z-average) and (B) zeta potential. Data are based on two independent experiments. 
Different formulations were tested keeping the amount of Armet-dsRNA constant (1 µg) and varying the 
unlocked BAPCs concentration. Differences between values were compared by one-way ANOVA using 
Bonferroni as post-test (N = 5). Statistical significance: (**) p < 0.01; (****) p < 0.0001. Non-statistical 
significance (ns) was considered when p > 0.05. Reprinted with permission from Avila, L. Adriana et al. 
2018. Delivery of lethal dsRNAs in insect diets by branched amphiphilic peptide capsules. Journal of 




levels of 3 µM glutathione (Figure 2.3 A).  This would indicate approximately 2-fold as much 
thiol present in solution compared to the amount of dsRNA, which would be expected if each 5’ 
end of the dsRNA was labeled. While fluorescent detection of the Atto633-labeled dsRNA did 
not improve after free thiol confirmation and longer incubation time of the dye at optimal 
temperature (25°C), the labeled dsRNA was fed to T. castaneum larvae complexed with and 
without BAPCs and visualized with confocal microscopy to determine if any fluorescence was 
able to be detected within the insect. To ensure excess free dye was properly removed from the 
labeled dsRNA solution, an agarose gel was run (Figure 2.3 B). While the weight of the dye is 







Figure 2.3 - Thiol Fluorometric Detection Results and Free Dye Detection of Labeled Armet-
dsRNA 
(A) Fluorescent reading from thiol fluorometric detection assay. Red - 30 µM glutathione standard; Cyan - 10 
µM glutathione standard; Blue - 1.8 µM Armet-dsRNA post thiol addition from 5’ EndTag Kit ; Black - 3 µM 
glutathione standard; Green - Blank (assay buffer and green dye alone). Ex: 490 nm. Em: 520 nm (B) Agarose 
gel. Lane 1, 1 kb DNA ladder by Oxygen; Lane 2 & 3, unlabeled Armet-dsRNA (296 bp); Lane 4, Atto633 
labeled dsRNA (296 bp); Lane 5, Atto633 maleimide dye alone (1.3 mM); Lane 6, Atto633 maleimide dye (1.3 
mM) with loading dye; Lane 7, loading dye alone; Lane 8, 1 kb DNA ladder by Biolabs.  
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small compared to the weight of the 296 bp Armet-dsRNA and is not able to be visually 
distinguishable in dsRNA labeled vs. unlabeled, the dye itself highly visible on the gel. These 
results indicate that any fluorescence detected after feeding, is likely due to dsRNA that has been 
covalently labeled, and not free dye. T. castaneum larvae were fed on a diet containing Atto633-
labeled Armet-dsRNA with and without complexion with BAPCs for 24 h, dissected and 
visualized using confocal microscopy (Figure 2.4). These initial results showed localization of 
dsRNA within fat body and malpighian tubule of the larvae. Visualization of the dsRNA within 
Fat Body was a surprising result, as it had not been visualized as a place for dsRNA localization 
in previous literature, to the best of our knowledge. While imaging these larvae however, it was 
also noted that an infection had occurred within the colony and was highly concentrated in each 
insect (noted in red circle in Figure 2.4 D). This could have affected the normal physiology of 
the insects and could have led to the fat body location, as well as false positives throughout the 
study.  
New colonies of T. castaneum were established, maintaining high level of sterility when 
rearing and selecting for experiments. With the healthy T. castaneum colonies, the experiment 
was repeated as described, and were visualized 8 h post feeding. Fluorescence was detected in 
the midgut epithelial cells, fat bodies, and Malpighian tubules of T. castaneum fed with dsRNA-
BAPC complexes, while T. castaneum fed with free dsRNA alone showed little to no 
fluorescence in the same regions (Figure 2.5). Figure 2.5 A and D show the midgut region, with 
A showing the delivery of dsRNA with BAPCs and D showing the delivery of dsRNA alone. 
The midgut is the only area of the gut that has exposed epithelial cells and is able to transfer 
materials from the midgut to the hemolymph. There appears to be accumulation of dsRNA in the 





Figure 2.4 - Localization of Fluorescently Labeled Armet-dsRNA in Infected T. castaneum Larvae 
Images taken after feeding. The fluorescence is shown as bright green on the bright-field background. All pictures 
were captured in the same condition in a LSM700 confocal microscope. (A) and (B) show fluorescently labeled 
Armet-dsRNA, delivered with and without BAPCs respectively, located in the fat body as emphasized by the 
arrows. (C) and (D) show fluorescently labeled Armet-dsRNA, delivered with and without BAPCs respectively, 
located in the malpighian tubule as emphasized by the arrows. While these images were taken, it was noted that the 
larvae seemed to be infected, highlighted by the red circle in panel D. Scale bar: 50 µm. N = 5. 
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detected in panel D, but there is slight coloration which would be expected as it passes through 
the body for excretion. Figure 2.5 B and E show fat bodies, with B showing dsRNA delivered 
with BAPCs and E showing dsRNA alone. The fat body in insects is involved in many metabolic 
functions, including the storage and release of energy [201]. It is a large organ distributed 
throughout the insect body preferentially surrounding the gut among other regions and provides 
maximal exposure to the hemolymph. Finally, Figure 2.5 C and F show the Malpighian tubule, 
with C showing the delivery with BAPCs and F showing the delivery sans BAPCs. Malpighian 
tubules act as the excretory and osmo-regulatory system, are surrounded by the hemolymph, and 
Figure 2.5 - Localization of Fluorescently Labeled Armet-dsRNA in T. castaneum  Larvae 
Images taken 8 h after feeding. The fluorescence is shown as magenta on the bright-field background. All pictures 
were captured in the same condition in a LSM700 confocal microscope. (A) midgut; (B) Fat Body; (C) Malpighian 
tubule; (D) to (F) are the same tissues in the Tribolium fed with Atto633 fluorescently labeled Armet-dsRNA alone. 
Scale bar: 20 μm. N = 5. Reprinted with permission from Avila, L. Adriana et al. 2018. Delivery of lethal dsRNAs 
in insect diets by branched amphiphilic peptide capsules. Journal of Controlled Release 273: 139-146. Copyright 
2018 Elsevier B.V. 
34 
are in close proximity to the fat body tissue [202]. Through these results it appears the oral RNAi 
effects in distal tissues is mediated by the exit of dsRNA from the midgut epithelial cells to the 
hemolymph and then accumulate in the Malpighian tubules and fat body. These results represent 
the first bio-accumulation study of orally administered dsRNA associated with nanoparticles in 
insets and first reported accumulation in fat body ingested from diet.  
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 Conclusions and Future Outlook 
In addition to the bioaccumulation of dsRNA, it would be beneficial to understand the 
bioaccumulation of BAPCs that help orally administer the dsRNA. Knowing where the BAPCs 
are able to locate within the insect, as well as when and where BAPCs and dsRNA disassociate 
from each other, would provide further insight to the systemic exposure of dsRNA in insects. 
While this experiment was attempted a few times, the level of detection for dye within BAPCs 
with the amount administered was difficult to distinguish. Further optimization of the amount of 
dye used, compatibility of dyes, concentration of BAPCs, and concentration of dsRNA while 
maintaining the N:P ratio, would be worth pursuing.  
It has previously been reported that when multiple dsRNAs are injected in T. castaneum 
they compete and result in a less effective RNAi response [203]. That was not the case for this 
study. This may be because both genes/proteins targeted in this study were a part of the same 
pathway. Looking at further oral delivery studies with dual dsRNA administered as well as 
completing further studies in this manner can help clear up the understanding of how or why 
some dsRNA may compete for RNAi.  
The success of T. castaneum lethality via oral BAPC delivery presents the opportunity for 
use in the field as an alternative or complementary insecticide to its chemical counterpart. This 
form of insecticide can be delivered by transformative RNAi or non-transformative RNAi. 
Transformative RNAi refers to transgenic plants, new genes inserted in nuclear DNA, and 
transplastomic plants, new genes inserted in chloroplasts. While these provide efficient long-
term control, low consumer acceptance, extensive regulatory process, and high production cost 
outweigh the benefits. Non-transformative RNAi methods, which are more accepted by 
consumers, include trunk injection, root absorption, bacterial dsRNA, symbionts, and sprayable 
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dsRNA. While these methods need a continuous supply of dsRNA, they also have a low cost per 
tree or acre, are feasible, and non-transgenic [177]. dsRNA-BAPC complexes hold the potential 
to be used for non-transformative RNAi, and researching these possible methods is a crucial next 
step. Additionally, understanding the short- and long-term effects of dsRNA-BAPC complexes 
in the environment is required prior to field application, and studies have been underway. For the 
future research of RNAi based insecticides resistance, biosafety, and ecological safety remain 
high concerns that have not been fully established [185].  
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Chapter 3 - Transdermal Uptake of BAP-MNB Complexes in Mice 
 Introduction 
The administration route for a medication should be decided upon based on the purpose 
as well as advantages and disadvantages for each route to achieve the highest effectiveness. [214, 
204]. There are numerous drug administration routes including oral, injection (subcutaneous, 
intramuscular, intravenous, and intradermal), mucosal, ocular, cutaneous, and transdermal. While 
oral delivery is the most convenient and is usually the safest and most cost efficient, some drugs 
are absorbed poorly in the digestive tract or destroyed by acid and digestive enzymes in the 
stomach [214, 222]. Subcutaneous injection is a popular alternative for many protein-based drugs 
and nucleic acids which are destroyed by the digestive tract [214]. This injection method delivers 
medication to the fatty tissue between the skin and muscle [217, 222]. Due to the limited 
availability of blood vessels in this tissue, there is a slow sustained rate of absorption; slower 
than intravenous or intramuscular injections but faster than intradermal injections [218, 222]. 
Medications typically delivered subcutaneously include insulin, hormones, morphine, some 
vaccines, and sometimes epinephrine [217]. Intramuscular injection delivers medication deep 
into the muscles and is used for most vaccines [219]. Intramuscular injections are used over 
subcutaneous or intravenous injections when a larger volume needs to be delivered, the drugs are 
irritating to veins, or a suitable vein is not able to be located [214, 219]. Medications delivered 
intramuscularly are absorbed faster than those delivered subcutaneously due to greater blood 
supply but can be ineffective if not delivered to the right muscular site [219, 222]. Delivering 
medications directly into the vein (Intravenous) provides rapid absorption and can also be 
controlled to provide slow constant administration [220, 222]. While intravenous medications are 
more consistently and completely absorbed with minimal discomfort compared to other injection 
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routes, not all medications can be delivered in this way and adverse effects can happen rapidly 
[222]. Intradermal injections are a shallow injection into the dermis using the Mantoux 
Procedure which injects the needle at a 5-15° angle to the skin and must be performed by skilled 
medical personnel [221, 222]. This method has the longest absorption time of all parenteral 
routes and is often used for tuberculosis, allergy, and local anesthesia tests [222].  
The skin has two main layers, the epidermis and the dermis. The epidermis is the 
outermost layer, acting as the physical barrier, and is composed of the stratum corneum (SC), 
stratum granulosum (SG), stratum spinosum (SS), and stratum basale (SB). The SC and SG 
together create a highly hydrophobic layer which prevents penetration of molecules larger than 
500 kDa [205]. The SC of this region is the rate limiting barrier for transdermal drug diffusion 
due to its thickness (15-20 μm). The next layer of the skin is the dermis, which is 1-2 mm thick, 
and is composed of the papillary dermis, reticular dermis, and hypodermis. Hair follicles, sweat 
glands, blood vessels, nerve fibers, and lymphatic vessels are all embedded in the dermis and can 
assist in transdermal drug delivery system (TDDS) penetration by trapping nanoparticles and 
creating a reservoir for long-term controlled release [205]. These dermal structures also provide 
easy access to systemic circulation, though once they enter blood vessels for systemic 
circulation, crossing the endothelium of blood vessels to exit near target tissues, is a limiting 
factor [205].  
Vaccination consists of activating the immune system with an infectious agent, or the 
components of the infectious agent, in a way that the host is not harmed, to build an effective 
immune response for potential future infections of that agent. Historically, vaccination has been 
accomplished by delivering specific antigens for the immune system to react with or by 
introducing a live mitigated infectious agent for replication within the host without causing the 
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disease, which presents the specific antigens to prepare the immune system [225]. More recently, 
the approach of delivering plasmid DNA encoding for the antigen of the infectious agent for in 
situ production and subsequent immune response has been developed and studied [225, 226, 227, 
228].  
The recent recognition the role skin plays in the immune system, beyond a physical 
barrier, has provided interest and motivation to develop vaccines that can be delivered in the skin 
and potentially eliminate the need for needles [216]. While vaccines are typically administered 
subcutaneously and intramuscularly, these tissues contain relatively few dendritic cells. The 
epidermis and dermis however are densely populated with antigen-presenting cells such as 
Langerhans cells (LCs), particularly in the epidermis [215, 249, 250, 251]. As the nucleic acid is 
able to enter the cytoplasm and nuclease of LCs, their activation prompts them to relocate from 
the epidermis to the T-cell area of the skin draining lymph nodes [249, 252]. Here they process 
the DNA to produce the antigen gene products and present them to T-cells to stimulate an 
immune response [249, 253]. This process provides potential for applications in immunotherapy 
and vaccine development though the skin [249, 254]. Instead of bypassing these skin immune 
cells via hypodermic injection, dermis injection can evoke a high immune response, and thus will 
require a lower vaccine dose [215]. However, the complex Mantoux Procedure, needle-phobias, 
and needle-associated infectious diseases push the development of needle-free skin vaccinations 
[216].   
Transdermal administration provides a non-invasive alternative to oral and hypodermic 
injection for body-wide delivery through a patch on the skin [213]. This method can slowly 
release drugs over several hours or days but is limited by how quickly a drug can penetrate the 
skin [214]. Transdermal drug delivery systems (TDDS) are controlled-release devices that 
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contain the drug for localized treatment of tissues underlying skin, or for systemic therapy after 
topical application to the skin surface [205]. Nanoparticles have been in the spotlight for 
transdermal delivery systems in the past few decades [234, 249, 255, 256, 257, 258]. Compared 
to other TDDS, nanoparticles show superior drug release, deeper penetration, and allow 
encapsulation of both hydrophilic and hydrophobic compounds [205, 259]. Transdermal drug 
exposure has several advantages over other routes. When delivered transdermally, the first-pass 
effect in the liver caused by oral exposure is avoided. This delivery method also decreases 
demand for multiple doses due to the long-term controlled release and increased compliance in 
patients has be observed [205].  
Nanoparticles can penetrate the skin through three pathways: intercellular lipid route, 
transcellular route, and follicular route (Figure 3.1). The intercellular route (Figure 3.1A) travels 
between corneocytes in the SC. Enhancers such as dimethyl-sulfoxide (DMSO) are used to 
accelerate drug penetration through reducing diffusional resistance to the lipid bilayer making 
the SC more permeable to externally applied solutes, which is a reversible effect [211, 212]. The 
Figure 3.1 - Simplified Representation of Nanoparticle Penetration Routes 
(A) Intercellular lipid route through the lipid bilayers. (B) Transcellular route through keratin-rich corneocytes. (C) 
Follicular route, also known as the shunt pathway, through hair follicles and sweat ducts. The light tan objects in the 
images represent Corneocytes as part of the Stratum Corneum, which is 10-20 µm thick. The darker tan objects 
represent Keratinocytes in the Epidermis, which is 50-100 µm thick. The large black structure represents a hair 
follicle and the purple arrows represent the respective transport routes.  
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transcellular route (Figure 3.1B) travels intracellularly through corneocytes, rather than around 
them. To accomplish this route the compound must pass through alternating hydrophilic (interior 
of cells) and hydrophobic (extracellular matrix) regions, which is unfavorable for most drugs 
[205]. The follicular route (Figure 3.1C) travels though dermal structures via follicular 
penetration. These dermal structures, which include hair follicles and sweat glands, make up less 
than 0.1% of the cutaneous surface, making them historically disregarded as a potential 
transdermal drug delivery route [205]. Recent studies on the follicular pathway have provided 
evidence that this pathway can provide accelerated transport due to the proximity to capillary 
vessels [223]. Additionally, these transdermal structures can function as a reservoir for 
nanoparticles (up to 2 mm into the skin) and can be manipulated for controlled release to provide 
a pathway for systemic delivery [205, 260]. Variations in efficiency and proposed advantages 
have been observed for this route, likely due to the range in density of follicles [205].  
The size, size distribution, zeta potential, and surface properties influence efficiency for 
nano-based delivery [205]. The sulfated proteoglycans on the surface of the skin cells create a 
large negative charge, making positively charged nanocarriers prime candidates for penetration 
through electrostatic interactions over negatively charged or neutral nanocarriers [204, 205]. Size 
dependence for transdermal delivery is debated among researchers. Small nanoparticles (10 nm) 
have been shown to passively penetrate the skin, while a much larger size range of 122-1000 nm 
were tested on porcine ear skin in vitro, with a 643 nm size showing the deepest follicle 
penetration [224]. Once nanocarriers cross the skin barriers, the immune system recognizes them 
and tries to clear them as fast as possible. Surface modification such as PEGylation of 
nanoparticles, in which the surface is coated in polyethylene glycol,  have shown to generate a 
“stealth” effect to avoid the immune system and increase the circulatory half-life [25]. 
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Nanocarriers that can facilitate systemic transdermal delivery, while carrying nucleic acid 
could provide a potential non-invasive route for DNA vaccinations and gene delivery for wound 
healing, skin cancers, and skin diseases [206, 229, 230, 231]. Gene therapy via skin delivery can 
address lack of targeted delivery of genes to diseased sites and cells, degradation of genes during 
delivery, and fast clearance in circulation, which are common challenges. The skin is also highly 
immunogenic, making it an ideal target for highly efficient vaccinations [206, 215]. In addition 
to this, transdermal delivery can be pain free with high efficiency and low side effects [206]. 
Transdermal delivery of nucleic acids can be categorized into physical, including microneedles 
and microporation; active, including electroporation, iontophoresis, and sonophoresis; and 
passive, including polymeric nanoparticles, liposomes, peptides, and dendrimers [231]. Several 
passive approaches such as viral vectors, cell penetrating peptides, liposomes, dendrimers, gold 
nanoparticles, and carbon nanotubules have been show to effectively delivery nucleic acid 
through skin delivery [206, 232, 233, 234, 235, 236].  
BAPCs were previously shown to deliver a DNA vaccine that encodes the HPV-16 E7 
oncoprotein effectively through intramuscular inoculation in mice [164]. If BAPCs can passively 
cross the skin barrier, they could provide an alternative DNA vaccination or gene therapy 
delivery route. For this pilot study, magnetic nanobeads (MNBs) were coated with a bilayer of 
h9 peptides to mimic standard BAPC formation and allowed to interact with the skin surface of a 
mouse to determine if they were able to penetrate the skin barrier and systemically circulate. The 
MNB core allowed for ease of recovery from the tissue samples.  
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 Materials and Methods 
 Peptide Synthesis 
The branched amphiphilic peptides bis(Ac-FLIVIGSII)-K-K4-C-CONH2, bis(Ac-
FLIVIGSII)-K-K4-CONH2, and bis(Ac-FLIVI)-K-K4-CONH2 and were synthesized and cleaved 
as previously described [160]. After cleavage the peptides were washed with diethyl ether three 
times, dissolved in water, and lyophilized before storage at room temperature. The peptides were 
purified by reversed phase HPLC and characterized using matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF/TOF).  
 
 BAPC Formation with Atto633 Fluorescent Dye 
A small amount of the peptides bis(h9) and bis(h5) were individually dissolved in 2,2,2-
Triuoroethanol (TFE), where they adopt a helical formation. The concentration was determined 
using molar absorptivity of phenylalanine in water at 257.5 nm, (ε = 194 cm-1M-1), noting that 
there are 2 phenylalanines present in each peptide. The absorbances were read in a 0.3 cm path 
Figure 3.2 - Sequence of h9-Cys, h9, and h5 peptides 
Sequences of the self-assembling branched peptides h9-Cys, h9, and h5. The peptides are N-terminal acetylated 
(Red), with the branch point lysine (green) with branches coming off the α-amino group of the N-terminus and the ε-
amino group of the side chain.  
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length quartz cuvette (Cary UV/Vis Spectrophotometer, Varian, Inc. Palo Alto, CA, USA). The 
peptides were then mixed together at an equimolar ratio to achieve a final concentration of 1 mM 
in 1 mL. This solution was incubated at room temperature for 10 min, followed by solvent 
removal under vacuum. Once the peptides were completely dried, 1 mL of  1.5 mM Atto633 
fluorescent dye (Atto-Tec GmbH, Germany) in water was added drop-wise, mixed well with a 
pipette, and incubated at room temperature for 30 min to allow the peptides to form dye-filled 
capsules. After this incubation period the solution was incubated at 4°C for 1 h to prevent 
capsule fusion, then incubated at room temperature again for 30 min prior to use [161].  
Upon completion of all incubation times, the solution was passed through a 0.22 μm 
polytetrafluoroethylene syringe-driven filter (EMD Millipore, Billercia, MA) and placed in an 
Amicon ultra-0.5 mL centrifugal cellulose filter with 30 kDa molecular weight cut-off (eMD 
Millipore, Billerica, MA) and centrifuged at 13,500 x g for 5 min in an Eppendorf  D benchtop 
centrifuge.  
 
 BAP-MNB preparation 
BAP-MNBs were prepared by Pavithra Natarajan. The 200 nm Super Mag Maleimide 
Activated NanoBeads lyophilized powder (Ocean Nanotech, San Diego, CA) contains 1 mg of 
Magnetic NanoBeads (MNBs) per 20 mg of lyophilized powder, i.e. 5% w/w of the beads. 1 mg 
MNBs contains 3x1010 beads. 5 mg of MNBs were suspended in 10 mL of 0.1 M HEPES buffer 
(pH 7.5). The mixture was vortexed well until the beads were completely suspended in solution, 
with 75% ethanol. 6 µmoles of h9-Cys peptide were added to the solution in small increments, 
vortexing between each addition to ensure proper dispersion and maximum available surface 
binding sites and placed on a shaker overnight at room temperature. After the overnight 
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incubation at room temperature, the solution was placed in a magnetic separation rack (1 Tesla, 
Permagen Labware, Peabody, MA, USA) for 2 h, followed by two washed to remove excess 
peptides and resuspended in TFE. Twelve μmoles of h9 peptide were added to the solution, 
vortexed, and placed in a sonicator for 5 min, followed by magnetic separation and resuspension 
in water. The solutions were placed in the magnetic separation rack (source) for another 10 mins, 
collected, and incubated at 4°C overnight. Following overnight incubation, the BAP-MNBs 
solution was sonicated and filtered through a sterile 0.22 μm syringe filter (EMD Millipore, 
Billercia, MA). The concentration of BAP-MNBs was then calculated using the Ferene-s assay 
Reference.  
 
 BAP-MNB DMSO Working Solution Preparation 
A 1 L 0.85% normal saline solution was prepared in deionized water. This solution was 
passed through a sterilization filter (EMD Millipore, Billercia, MA) and kept at 4°C maintaining 
sterile techniques. BAP-MNBs (5x109 particles) suspended in saline, prepared as previously 
described, was brought to a final volume of 1 mL containing 0.1% DMSO. This solution was 
incubated at room temperature for 30 min and remixed by inversion immediately prior to use, to 
ensure adequate dispersion.  
 
 Mice 
Male mice (C57BL/6, 8-10 weeks old) were obtained from Jackson Laboratories and 
maintained in the Division of Biology at Kansas State University.  All mice were kept in a 12 h, 
light to dark, temperature-controlled room and allowed food and water ad libitum. All mice were 
housed in a specific pathogen free facility. All research was approved by the Institutional Animal 
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Care and Use Committee (IACUC) and conducted in cooperation with the Animal Welfare Act 
and other federal statues and polices that concern the animals.  
 
 Exposure and Conditions 
Individually, a mouse was placed in a modified 50 
mL tube, where the tip was removed to allow the mouse to 
breath and a hole was created in the lid to allow the tail to 
be exposed outside of the tube, to restrain the mouse while 
the tail was exposed to 1 mL of the BAP-MNBs solution, 
prepared as previously described, for the given exposure 
time (Figure 3.3). After exposure the mouse was returned 
to its cage for an incubation period of 1 h, 8 h, or 24 h, to 
allow the BAP-MNBs to circulate. After this incubation 
period the mice were euthanized by CO2 exposure followed 
by cervical dislocation. The kidney, spleen, large left liver 
lobe, and right lung were removed, and feces were extracted 
from the rectum. Samples were immediately placed in at      
-80°C and stored for up to two weeks prior to analysis. 
There were four exposure times in which the tail was 
dipping in the BAP-MNB solution (1 min, 5 min, 15 min, 
and 30 min), with an additional exposure time of 30 minutes for a solution without DMSO, and 
three incubation periods (1 h, 8 h, and 24 h) prior to tissue collection, which were all performed 
Figure 3.3 - Apparatus Used for 
Administering BAP-MNB Solutions 
A hole was created at the tip of the tube, to 
allow airflow and for the mouse to breath, 
and in the lid to allow for the tail to 
protrude from the tube. The tail was able 
to be placed in 1 mL of the BAP-MNBs 
solution for the given exposure time while 
the mouse was restrained. The binder clips 
seen in the image prevented the tube from 
rolling with the mouse movements.    
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in triplicate, except for one group which was only able to be performed in duplicate due to a 
premature death (Table 3.1)  
 
 
 MNB Acquisition and Quantification 
Organ and fecal samples were removed from -80°C and allowed to thaw at room 
temperature for 30 min. Individually, the samples were homogenized using a glass homogenizer 
in 1mL of a solution containing 4% SoluLyse-M (Genlantis, San Diego, CA, USA) in Normal 
Saline. The samples were then placed on a ~1 Tesla magnetic separator (Permagen Labware, 





Incubation time within 












1 h 2 
8 h 3 
24 h 3 
5 min 
1 h 3 
8 h 3 
24 h 3 
15 min 
1 h 3 
8 h 3 
24 h 3 
30 min 
1 h 3 
8 h 3 










1 h 3 
8 h 3 
24 h 3 
Table 3.1 - Summary of Experimental Groups 
There are four exposure times (1 min - 30 min) for dipping the mouse tail in a solution 
containing BAP-MNBs in 0.1% DMSO as well as a control group with an exposure time 
of 30 min in a solution containing BAP-MNBs without DMSO. Each exposure time was 
followed by circulatory times of 1 h, 8 h, or 24 h and 3 trials were performed for each set 
of conditions.   
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 MNB Quantification/ Ferene-S Assay 
The iron present in the samples after magnetic separation, was quantified according to the 
protocol by Hedayati et al. [207]. Samples were placed in a white 96-well plate and the 
absorbances were read using Bio-rad model 680 microplate reader (Bio-rad, USA) at 600 nm. 
The standards were graphed and used to calculate the μg/mL of iron in each sample. Using the 
information that each magnetic nanobead contains 1.04x10-8 μg of iron, the μg/mL of iron data 
was converted into the number of magnetic nanobeads (Table A.3). These were then normalized 
based on the weight of the sample the beads were extracted from (Table A.4).  
 
 Tail Sectioning 
One mouse from each condition of 15 min exposure - 1 h incubation, 15 min exposure - 8 
h incubation, and 15 min exposure - 24 h incubation, were administered a solution that contained 
BAP-MNBs as well as Atto633 encapsulated BAPCs. The tails from these mice were removed at 
the same time as the other tissue samples and immediately placed in 4% formalin with an 
overnight incubation at 4°C. After overnight incubation, the tails were transferred to 70% ethanol 
and stored at 4°C. These samples were submitted to the Histopathology lab as part of the Kansas 
State Veterinary Diagnostic Laboratory where they were subjected to decalcification of the 
tailbone using 10% HCL, paraffin embedded, cross-sectioned, and placed on a slide for confocal 
visualize or Prussian blue staining.    
 
 Prussian Blue Staining of Cells for Visualization of MNBs within Cells  
Potassium Ferrocyanide is used to stain the magnetic iron nanobeads, to visualize them 
within cells. Fresh stain is prepared by mixing equal volumes of 10% Potassium Ferrocyanide 
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solution (5 g in 50 mL deionized water) and 20% HCl (10 mL HCl to 50 mL deionized water). 
One mL of fresh acidified potassium ferrocyanide solution is added to the slide, allowed to 
incubate at 37°C for 30 min. The stain is then aspirated out and the tail section was washed with 
deionized water to remove excess stain. The tail sections were then imaged using a light 
microscope at 45x magnification and a Nikon lens attached to the eyepiece for capturing images. 
The MNBs are visualized as Prussian blue aggregates within cells (Figure B.2).  
 
 Confocal Laser Scanning Microscopy 
Images shown in Figure 3.3 and Figure 3.6 were captured using a confocal LSM 700 
laser-scanning microscope (Carl Zeiss, Gottingen, Germany) using a 639 nm laser. Green color 
was used for ease of visualization and does not reflect true fluorescence color of Atto633 dye.  
  
 Statistical Analyses 
Statistics were performed using IBM SPSS Statistics software (Version 25, IBM 
Corporation, Armonk, NY). Statistical significances for 1 h, 8 h, and 24 h incubation period data 
were determined using a two-way ANOVA test followed by Bonferroni’s post-test. Data are 
mean ± standard error, unless otherwise stated. 
A two-way ANOVA was conducted to examine the effects of exposure time and tissue 
location on number of MNBs for a 1 h incubation period. Each exposure time was completed in 
triplicate, except for the exposure time of 1 min which was only able to be completed in 
duplicate. Residual analysis was performed to test for the assumptions of the two-way ANOVA. 
There were no outliers are assessed by inspection of a boxplot. The assumption of normality, as 
assessed by Sharpio-Wilk’s test, was satisfied for group combinations of exposure time and 
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tissue location (p > 0.05) except for the following combinations which violated the assumption 
of normality (p < 0.05): 15 min exposure in feces, 30 min exposure in liver, 30 min exposure in 
lungs, 30 min exposure in feces, 30 min exposure without dmso in lungs and 30 min exposure 
without dmso in feces. Transformation did not address this problem. The assumption of 
homogeneity of variances was violated, as assessed by Levene’s test for equality of variances, p 
< 0.0005). Transformation did not address this problem and the two-way ANOVA was carried 
out regardless due to the equal group sample sizes. The interactions effect between exposure 
time and tissue location on number of MNBs was not statistically significant, F(2,52) = 0.500, p 
= 0.934, partial η2 = 0.151. Therefore, an analysis of the main effect for exposure time was 
performed, which showed statistically significant main effect of exposure on MNBs, F(1,52) = 
1.414, p = 0.245, partial η2 = 0.112. An analysis of tissue location also showed no statistically 
significant main effect of tissue on MNBs, F(1,52) = 1.160, p = 0.341, partial η2 = 0.093. 
A two-way ANOVA was conducted to examine the effects of exposure time and tissue 
location on number of MNBs for an 8 h incubation period. Each exposure time was completed in 
triplicate. Residual analysis was performed to test for the assumptions of the two-way ANOVA. 
There were no outliers are assessed by inspection of a boxplot. The assumption of normality, as 
assessed by Sharpio-Wilk’s test, was satisfied for group combinations of exposure time and 
tissue location (p > 0.05) except for the following combinations which violated the assumption 
of normality (p < 0.05): 1 min exposure in lungs, 5 min exposure in kidney, 30 min exposure in 
spleen, 30 min exposure in liver, 30 min exposure in lungs, 30 min exposure without DMSO in 
kidney. Transformation did not address this problem. The assumption of homogeneity of 
variances was violated, as assessed by Levene’s test for equality of variances, p < 0.0005). 
Transformation did not address this problem and the two-way ANOVA was carried out 
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regardless due to the equal group sample sizes. This should be considered when interpreting the 
results. There was a statistically significant interaction between exposure time and tissue location 
on number of MNBs, F(2.52) = 2.781, p = 0.003, partial η2 = 0.471. Therefore, an analysis of 
simple main effects for exposure time was performed with statistically significance receiving a 
Bonferroni adjustment and being accepted at the p < 0.025 level. There was a statistically 
significant difference in mean number of MNBs for location in spleen with 1 min, 5 min, 15 min, 
30 min, and 30 min without DMSO exposure times, F(2,52) = 14.387, p <0.0005, partial = 0.535. 
All pairwise comparisons were run for each simple main effect with reported 95% confidence 
intervals and p-values Bonferroni-adjusted within each simple main effect. Mean number of 
MNBs for spleen location after 1 min, 5 min, 15 min, 30 min, and 30 min without DMSO 
exposure times were 4.35E9  4.32E9, 2.34E9  1.37E9, 1.31E10  1.02E10, 3.40E8  5.89E8, 
and 6.58E8  1.01E9, respectively. 15 min exposure time had a statistically significantly higher 
mean number of MNBs than 1 min exposure, 8.72E9 (95% CI, 2.99E9 to 1.45E10), p < 0.0005, 
5 min exposure, 1.07E10 (95% CI, 5.00E9 to 1.65E10), p < 0.0005, 30 min exposure, 1.27E10 
(95% CI, 7.00E9 to 1.85E10), p <0.0005, and 30 min exposure without DMSO 1.24E10 (95% 
CI, 6.68E9 to 1.82E10), p < 0.0005. Mean number of MNBs after 15 min exposure in the kidney, 
spleen, liver, lung, and feces tissues were 1.02E9  1.49E9, 1.31E10  1.02E10, 3.20E8  
1.95E8, 1.68E9  1.13E9, and 1.03E9  1.11E9 respectively. Spleen tissue had a statistically 
significantly higher mean number of MNBs than kidney tissue, 1.21E10 (95% CI, 6.32E9 to 
1.78E10), p < 0.0005, liver tissue 1.28E10 (95% CI, 7.02E9 to 1.85E10), p < 0.0005, lung tissue, 
1.14E10 (95% CI, 5.66E9 to 1.71E10), p < 0.0005, and feces, 1.20E10 (95% CI, 6.31E9 to 
1.78E10), p < 0.0005. 
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A two-way ANOVA was conducted to examine the effects of exposure time and tissue 
location on number of MNBs for a 24 h incubation period. Each exposure time was completed in 
triplicate.  Residual analysis was performed to test for the assumptions of the two-way ANOVA. 
There were no outliers are assessed by inspection of a boxplot. The assumption of normality, as 
assessed by Sharpio-Wilk’s test, was satisfied for group combinations of exposure time and 
tissue location (p > 0.05) except for the following combinations which violated the assumption 
of normality (p < 0.05): 5 min exposure in spleen, 5 min exposure in liver, 15 min exposure in 
spleen, 30 min exposure in spleen, 30 min exposure in lungs, 30 min exposure without DMSO in 
spleen, 30 min exposure without DMSO in feces. Transformation did not address this problem. 
The assumption of homogeneity of variances was violated, as assessed by Levene’s test for 
equality of variances, p < 0.0005). Transformation did not address this problem and the two-way 
ANOVA was carried out regardless due to the equal group sample sizes. The interactions effect 
between exposure time and tissue location on number of MNBs was not statistically significant, 
F(2,52) = 0.720, p = 0.761, partial η2 = 0.187. Therefore, an analysis of the main effect for 
exposure time was performed, which showed statistically significant main effect of exposure on 
MNBs, F(1,52) = 1.348, p = 0.265, partial η2 = 0.097. An analysis of tissue location also showed 
no statistically significant main effect of tissue on MNBs, F(1,52) = 1.416, p = 0.242, partial η2 
= 0.102.  
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 Results and Discussion 
Initial work performed by a former lab member looked at the potential transdermal 
uptake of BAPCs in mouse tails that had been obtained from deceased mice. The tails were 
subjected to dipping in a solution containing 0.1% DMSO with 100 μM of BAPCs encapsulating 
Atto633 fluorescent dye. These tails were dipped in the solution for four short durations of time: 
1 s, 5 s, 10 s, and 20 s in triplicate. These samples were then paraffin embedded and cross 
sections were prepared for visualization via confocal microscopy. Fluorescence was seen at the 
epidermis and in hair folicles for these initial exposures, indicating the potential for BAPCs to 
penetrate transdermally when delivered to a mouse with an active metabolism and circulatory 
system. Autofluorescence is often seen in hair follicles as well, so to determine if there was a 
true transdermal interaction further studies in live mice were performed.  
The nanoparticles for this study are modified versions of the previously discussed 
traditional hollow BAPCs. Instead, these nanoparticles contain a 200 nm mangnetic nanobead 
(MNB) core, surrounded by a dual layer of the branched amphiphilic peptide h9, mimiking the 
Figure 3.4 - Schematic of BAP-MNBs Formation 
Simplified schematic of BAP-MNBs formation. A 200 nm MNB is first coated in a layer of h9-Cys 
peptides, where the red dot indicates the cysteine residue on the C-terminus of the branched amphiphilic 
peptide. Next h9 peptides are added to form the bilayer of amphiphilic peptides around the MNB. Peptides 
are not to scale. Created with biorender.com. 
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peptide bilayer of hollow BAPCs (Figure 3.4). The first layer consists of the h9-Cys peptides, 
where an additional cysteine thiol is at the C-terminus of the sequence (Figure 3.2), which are 
directly bound to the MNB using thiol-maleimide interaction chemistry. The thiol group of the 
cysteine reacts with the maleimide adduct on the surface of the MNB and forms a covalent bond, 
covering the surface of the MNBs in a layer of h9-Cys peptides where the brached N-terminuses 
are exposed. Additional h9 peptides are added to form the bilayer of peptides as previously 
described (Figure 3.4). These nanoparticles will be referred to as branched amphiphilic peptide-
magnetic nanobeads (BAP-MNBs). BAP-MNBs are useful for this study as they circulate 
through the body similarly to a BAPC due to the boundary peptide bilayer, but are easily 
separated one released from the tissues using a strong neodymium magnet. These nanoparticles 
were designed in the same fashion as BAP-AuNPs as described in Natarajan et al. [248].   
For further studies in passive transdermal uptake, a range of exposure and circulatory 
times were studied. There were four exposure times (1 min - 30 min) for dipping the mouse tail 
in a solution containing BAP-MNBs in 0.1% DMSO as well as a group with an exposure time of 
30 min in a solution containing BAP-MNBs without DMSO. Each exposure time was followed 
by three different incubation times (1 h, 8 h, and 24 h) prior to tissue collection, to allow the 
MNBs to enter the bloodstream and accumulate in different tissues. DMSO was used as an 
enhancer for uptake as previously described, at a concentration of 0.1% in saline, due to the 
potential toxicity at higher concentrations for transdermal use [237, 238, 239]. The average 
number of MNBs per gram of tissue, was calculated based on the iron content that was captured 
by the magnetic separator (Table B.3) and grouped by incubation time and tissue in Figures 3.5 - 
3.7. On average 1 mL of blood will contain 0.5 mg of iron, which equates to approximately 8-12 
ng of iron per red blood cell [261, 262]. Some tissues such as the spleen and liver also have a 
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high iron concentration, and thus it is important to separate endogenous iron from the BAP-
MNBs using the magnetic separation rack [270].  If there was excess iron captured by the 
magnetic separator, the samples with a higher red blood cell content could result in higher levels 
of iron detected, however no studies have shown magnetic separation racks to be able to capture 
endogenous iron. If BAP-MNBs are able to enter the bloodstream, and potentially become 
entrapped, tissue samples with higher blood content would reflect higher levels of MNBs 
detected. Further studies to clarify the baseline level of iron present, the background detected by 
the ferene-s assay, as well as the ability of BAP-MNBs to enter and/or exit the circulatory system 
would provide further insight.  
The size of nanoparticles is a key factor in the biodistribution and clearance route taken. 
Small nanoparticles (less than 30 nm in diameter) have been shown to be rapidly cleared by renal 
excretion [240, 241, 242] . This is due to the small pore sizes in the renal corpuscles which help 
filter the blood to produce urine. Adversely, larger nanoparticles (150-300 nm in diameter) are 
rapidly taken up by the mononunclear phagocytic system cells and accumulate in the liver and 
spleen. [208, 243, 240, 244]. Some studies have shown that medium sized nanoparticles (30-150 
nm) are also taken up by the mononuclear phagocytic system cells in bone marrow, heart, 
kidney, and stomach [240, 245, 246]. If these size-dependent clearance routes are true for all 
nanoparticles, 200 nm BAP-MNBs that were able to enter the circulatory system would be 
expected to accumulate the most in the liver and spleen.  
The average number of MNBs per gram of tissue for 1 hour incubation, post exposure are 
summarized in Figure 3.5 with three animals per treatment, with exception of 1 min exposure 
which consisted of two animals, due to a premature death before the study. The number of 
detectable MNBs recovered fell within the range of 106-1011 MNBs per gram of sample tissue 
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for each exposure time (1-30 min), with or without DMSO, and for each tissue type, while some 
samples showed no detectable levels of MNBs. From these trends, for a 1 h incubation time, the 
exposure time does not seem to strongly influence the number of MNBs that are able to penetrate 
or the locatoin of MNBs among the tissues assessed. It is important to note that the group which 
was treated with a BAP-MNBs solution without DMSO, shows comparable levels of MNBs 
present in all tissue types, and thus DMSO does not appear to be significant for the transdermal 
penetration of BAP-MNBs. The higher levels of MNBs within the feces samples, could indicate 
that a large portion of MNBs are already being excreted after only 1 h of circulation.  
The interaction effect between the tissue location of the MNBs and the exposure time on 
the number of MNBs detected with a 1-hour incubation period was determined to not be 
statistically significant as assessed by a two-way ANOVA. Further analysis of the main effects 
for tissue location and exposure time both showed no statistically significant effect on the 
number of MNBs detected. The main effect is the overall measure of effect of one factor on the 
dependent variable, ignoring the other factor:  the effect of tissue location on the number of 
MNBs, ignoring the exposure time and the effect of exposure time on the number of MNBs, 
ignoring tissue location. This analysis was carried out due to no statistically significant 
interaction effect on the number of MNBs between the two variables. 
The average number of MNBs per gram of tissue for 8 h incubation post exposure are 
summarized in Figure 3.6. The number of detectable MNBs fell within the range of 107-1011 
MNBs per gram of sample tissue for each exposure time (1-30 min), with or without DMSO, and 
for each tissue type. Some samples did not contain detectable levels of MNBs. This range of 
MNBs is much more diverse than that of the 1 h incubation time. There is an increase in the 
number of MNBs located in the spleen for lower exposure times (1-15 min), while there seems to 
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be a decrease in the number of MNBs located in the liver for a 1 min exposure time, as compared 
to 1 h incubation time. The increased accumulation in the spleen indicates that MNBs could be 
localized to the spleen as early as 1 h post exposure and continue to accumulate 8 h post 
exposure. The lower level of MNBs present in the liver and lungs for 1 min exposure, could 
indicate that these MNBs are excreted from these areas by 8 h, but this trend is not consistant for 
the other exposure times, and further studies will need to be conducted to further understand the 
biological accumulation and excretion.  
The interaction effect between the tissue location of the MNBs and the exposure time on 
the number of MNBs detected with an 8-hour incubation period was determined to statistically 
significant based on the F-value of 2.781, which had p-value of 0.003 and partial eta squared 
value of 0.471. If the null hypothesis, that there is no significant difference between groups, is 
true the F-value would be close to 1.0. A larger F-value indicates the variation among group 
means are more than you would expect to see by change. The p-value is the probability of 
observing the given F-value given the null hypothesis is true. The partial eta squared (η2) is a 
measure of effect size and reflects the percentage of variance in the number of MNBs detected 
explained by the factors in the sample. This means that 47.1% of the variance in number of 
MNBs detected is due to the tissue location and exposure time, while all other variance in the 
number of MNBs detected is due to experimental variance and chance. This statistically 
significant interaction indicates that the effect that exposure time has on the number of MNBs 
detected, depends on the tissue location. Due to this interaction effect, analysis of simple main 
effects for each factor (tissue location and exposure time) were conducted. Simple main effects 
determine the effect of one factor within one level of the other factor. The simple main effects 
for exposure time are the effects of exposure time in each tissue type. There were no statistically 
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significant effects of exposure time in the mean number of MNBs detected in the kidney, liver, 
lungs, or feces, but there was a statistically significant difference in the mean number of MNBs 
detected within the spleen between each exposure time based on the F-value of 14.387, which 
had a p-value of <0.0005 and partial eta squared value of 0.535. The 15 min exposure time had a 
statistically significant higher mean number of MNBs within the spleen than the 1 min, 5min, 30 
min, and 30 min without DMSO exposure times (p < 0.0005) and the spleen had a statistically 
significant higher mean number of MNBs detected with 15-minute exposure than the kidney, 
liver, lungs, or feces (p < 0.0005). It is important to note here that the homogeneity of variances 
for this data set was violated and could not be fixed by a simple transformation, which could 
impact the significance interpretation of the two-way ANOVA. 
The average MNBs per gram of tissue for 24 h incubation time are summarized in Figure 
3.7. The number of dectectable MNBs fell within the range of 106-1011 MNBs per gram of 
sample tissue for each exposure time (1-30 min), with or without DMSO, and for each tissue 
type. Some samples did not have detectable levels of MNBs. Two of the three trials for 5 minute 
exposure had no detectable levels of MNBs within the liver. This anomaly should be re-
evaluated with repeated studies. As compared to 8 h incubation, similar levels of MNBs after 24 
h incubation are present within the spleen, further suggesting this as a main site of accumulation. 
Elevated levels within the feces, also indicates that BAP-MNBs are continually being excreted, 
even 24 h post exposure.  
The interaction effect between the tissue location of the MNBs and the exposure time on 
the number of MNBs detected with a 24-hour incubation period was determined to not be 
statistically significant as assessed by a two-way ANOVA. Further analysis of the main effects 
for tissue location and exposure time both showed no statistically significant effect on the 
59 
number of MNBs detected. The main effect is the overall measure of effect of one factor on the 
dependent variable, ignoring the other factor:  the effect of tissue location on the number of 
MNBs, ignoring the exposure time and the effect of exposure time on the number of MNBs, 
ignoring tissue location. This analysis was carried out due to no statistically significant 
interaction effect on the number of MNBs between the two variables. 
The level of MNBs present for the groups administered without DMSO are at similar 
levels to the other exposure times with DMSO on average. When looking at the data for all three 
trials however, (Table B.2) there are some tissues and circulation times that did not have 
detectable levels of MNBs; this variability should be studied in more detail. These results could 
indicate that DMSO is not necesarry for pentration of BAP-MNBs.  
In an attempt to visualize the mode of entry through the skin, one mouse from each of the 
following conditions was administered a solution that also contained 100 µM of Atto633-
encapsulated BAPCs: 15 min exposure - 1 h incubation; 15 min exposure - 8 h; and 15 min 
exposure - 24 h incubation. For these three mice, the tail was also collected for cross-section 
analysis, just as the preliminary study by a former lab member was performed. While 
autofluorescence is likely present from hair follicles, if many BAPCs accumulate within dermal 
structures or penetrate further through the skin as compared to the pre-liminary trails where no 
active metabolism or circulation was present, they would be able to be visualized. Confocal 
imaging of these tail samples showed a minimal level of fluorescence and was likely the basal 
level from autofluorescence (Figure B.1) [247]. Nanoparticles and molecules that use the 
follicular route, are captured to provide a reservoir and have been shown to have storage time in 
the hair follicles for up to 10 days [205]. Thus, the presence of potential Atto633-encapsulated 
BAPCs in the epidermis and dermal structures at 24 h post exposure would be expected for this  
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30 min No DMSO
Error Bars: SEM
Figure 3.5 - Mean MNBs/g for 1 Hour Incubation Time 
Data are shown as mean ± standard error, unless otherwise stated. N = 3 for each exposure time, except for 1 min N 
= 2. The bars represent the mean number of MNBs per gram of tissue in sample. A two-way ANOVA to examine 
the effects of exposure time and tissue location of MNBs on the number of MNBs was conducted and found that the 
interaction effect between exposure time and tissue location was not statistically significant. Analysis of main 































30 min No DMSO
Error Bars: SEM
***
Figure 3.6 - Mean MNBs/g for 8 Hours Incubation Time 
Data are shown as mean ± standard error, unless otherwise stated. N = 3 for each exposure time. The bars represent 
the mean number of MNBs per gram of tissue in sample. A two-way ANOVA to examine the effects of exposure 
time and tissue location of MNBs on the number of MNBs was conducted and found that the interaction effect 
between exposure time and tissue location was statistically significant (p = 0.003). Analysis of simple main effects 
for tissue location and exposure time was performed and showed a statistically significant difference in mean 




































30 min No DMSO
Error Bars: SEM
Figure 3.7 - Mean MNBs/g for 24 Hours Incubation Time 
Data are shown as mean ± standard error, unless otherwise stated. N = 3 for each exposure time. The bars represent 
the mean number of MNBs per gram of tissue in sample. A two-way ANOVA to examine the effects of exposure 
time and tissue location of MNBs on the number of MNBs was conducted and found that the interaction effect 
between exposure time and tissue location was not statistically significant. Analysis of main effects for exposure 
time and tissue location were performed and showed no statistical significance 
 
63 
route. An untreated control mouse tail should be processed and visualized under the same 
conditions to verify the level of autofluorescence. Since MNBs were also used in these studies, 
cross-sections from the same tails were used to visualize MNBs with Prussian blue staining. 
Prussian blue is an insoluble bright blue pigment that formulates when potassium ferrocyanide 
encounters ferric ions, resulting in ferric ferrocyanide, also known as Prussian blue. A few 
MNBs or MNB aggregates were visualized, but not in a large quantity (Figure B.2). These tail 
sections were not taken in triplicate and thus are not a valid representation of the population. As 
such, visualizing these MNBs and/or BAPCs cannot provide conclusive insight at this time. 
Overall this pilot study showed some interesting and useful insight for the potential use of BAP-
MNBs and/or BAPCs via transdermal uptake and warrants additional investigation.  
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 Conclusions and Future Outlook 
The results shown were part of a pilot study to determine the potential of BAP-MNBs 
and/or BAPCs for transdermal delivery. While these initial results provide some insight, there 
are still a lot of remaining questions and conditions to be addressed. Looking at the full 
biodistribution and pharmacokinetics of BAP-MNBs and/or BAPCs via transdermal delivery, 
intravenous delivery, or oral delivery are needed to understand how the nanocarriers behave in 
vivo. In addition to looking at more tissues and fluids such as blood, brain, and urine among 
others, important parameters of pharmacokinetics to measure include maximum concentration, 
circulatory half-life, clearance, area under the curve, and mean resident time which is the average 
time a molecule stays in the body [209].  
Previous studies on biodistribution of nanoparticles that vary in size, show that larger 
nanoparticles tend to accumulate less than the smaller nanoparticles, and in different areas [210, 
240]. These larger nanoparticles also tend to have much shorter half-lives, which could 
contribute to the lower accumulation [208]. These measurements and observations for 200 nm 
BAP-MNBs, 50 nm BAP-MNBs, 20 nm locked BAPCs, all with or without nucleic acid such as 
pDNA or dsRNA, would provide invaluable data for the future of BAPCs in vivo and the field of 
nanodelivery systems. Additionally, if passive penetration is not as robust as initially thought, 
delivering BAPCs and nucleic acid-BAPC complexes via active or mechanical transdermal 
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Appendix A - Chapter 2 Supplemental Data  
 
  
Figure A.1 - AFM of BAPC Complexes 
(A) Atomic Force Microscopy (AFM) image analysis of the BAPC nanoparticles (40 μM). (B) 
AFM image analysis of dsRNA-BAPC complexes (1 μg and 40 μM respectively). Data and 
images collected by another lab member. Reprinted with permission from Avila, L. Adriana et 
al. 2018. Delivery of lethal dsRNAs in insect diets by branched amphiphilic peptide capsules. 
Journal of Controlled Release 273: 139-146. Copyright 2018 Elsevier B.V. 
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Figure A.2 - Survival Curves Showing Effect of dsRNA-BAPC Complexes in T. 
castaneum 
Early-instar larvae were fed wheat-flour/yeast extract diet supplemented with Armet- and 
BiP-dsRNA alone or together (1μg; 500 ng of each when fed together) with or without 
BAPCs. Day 1 represents the first day of feeding. After 6 days, the insects were transferred 
to the standard diet, lacking dsRNA or BAPC additions. Diseased Tribolium were counted 
on a daily basis. The number of insects on day 1 were 35 (diet alone); 30 (water plus 
CaCl2); 50 (BAPCs only control); 30 (Armet-dsRNA alone); 30 (BiP-dsRNA alone); 30 
(BiP-dsRNA/BAPC complexes); 30(BiP-Armet-dsRNA/BAPC complexes). Pupation 
started over a range of days, averaging about day 30, with eclosion (emergence of adults 
from pupae) over a range starting about day 40. No deaths occurred in the adult stage. 
Statistical significance: (*) p < 0.05, (**) p < 0.01, versus control groups treated with naked 
BiP-dsRNA or BiP-Armet-dsRNA. Non-statistical significance (ns) was considered when p 
> 0.05. Differences between values were compared by Log-rank (Mentel-Cox) test. Some 
diet was prepared by Kayla Nutsch, other data collection and T. castaneum monitoring was 
carried out by other lab members. Reprinted with permission from Avila, L. Adriana et al. 
2018. Delivery of lethal dsRNAs in insect diets by branched amphiphilic peptide capsules. 
Journal of Controlled Release 273: 139-146. Copyright 2018 Elsevier B.V. 
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Appendix B - Chapter 3 Supplemental Data 
  
Incubation 
Time / Trial 
Exposure 
Time (min) 
Kidney (g) Spleen (g) Lungs (g) Liver (g) Feces (g) 
1 h - Trail 1 
30m 0.194 0.069 0.13 0.467 0.043 
15m 0.219 0.087 0.082 0.272 0.061 
5m 0.205 0.086 0.053 0.487 0.067 
1m 0.221 0.067 0.146 0.506 0.151 
No30m 0.241 0.072 0.143 0.461 0.165 
1 h - Trial 2 
30m 0.205 0.017 0.123 0.476 0.153 
15m 0.184 0.087 0.184 0.595 0.101 
5m 0.257 0.027 0.12 0.552 0.023 
1m 0.174 0.091 0.14 0.6 0.126 
No30m 0.221 0.075 0.128 0.593 0.041 
1 h - Trial 3 
30m 0.154 0.075 0.122 0.481 0.087 
15m 0.212 0.066 0.175 0.418 0.121 
5m 0.227 0.102 0.075 0.549 0.082 
No30m 0.146 0.087 0.139 0.472 0.046 
8 h - Trial 1 
30m 0.23 0.047 0.126 0.396 0.123 
15m 0.236 0.074 0.075 0.345 0.08 
5m 0.23 0.08 0.131 0.457 0.053 
1m 0.181 0.096 0.145 0.25 0.057 
No30m 0.188 0.035 0.047 0.346 0.108 
8 h - Trial 2 
30m 0.219 0.08 0.118 0.217 0.119 
15m 0.161 0.061 0.144 0.373 0.064 
5m 0.233 0.061 0.079 0.414 0.102 
1m 0.218 0.062 0.148 0.307 0.055 
No30m 0.226 0.075 0.122 0.355 0.138 
8 h - Trial 3 
30m 0.198 0.048 0.064 0.41 0.108 
15m 0.162 0.049 0.044 0.3 0.123 
5m 0.232 0.078 0.063 0.44 0.122 
1m 0.201 0.086 0.168 0.384 0.064 
No30m 0.189 0.061 0.154 0.328 0.107 
24 h - Trial 1 
30m 0.233 0.096 0.164 0.52 0.083 
15m 0.261 0.067 0.117 0.343 0.143 
5m 0.211 0.074 0.131 0.451 0.079 
1m 0.223 0.075 0.06 0.558 0.133 
No30m 0.213 0.061 0.04 0.513 0.128 
24 h - Trial 2 
30m 0.237 0.082 0.05 0.58 0.103 
15m 0.201 0.082 0.109 0.497 0.118 
5m 0.228 0.081 0.08 0.476 0.143 
1m 0.23 0.091 0.154 0.467 0.074 
No30m 0.223 0.017 0.107 0.292 0.122 
24 h - Trial 3 
30m 0.18 0.077 0.144 0.451 0.155 
15m 0.202 0.01 0.122 0.439 0.217 
5m 0.203 0.081 0.102 0.479 0.166 
1m 0.214 0.052 0.155 0.449 0.109 
No30m 0.234 0.093 0.213 0.439 0.092 
 
Table B.1 - Weight of Tissues 
Weight of tissues collected. Incubation time refers to the time post exposure until euthanasia. Exposure time refers 
to the amount of time the tail was dipped into the solution containing BAP-MNBs with or without DMSO. 15m 





















1 h - Trail 1 
30m 2.53E+08 7.11E+08 4.16E+07 1.98E+08 2.35E+10 
15m 6.22E+08 1.57E+09 1.13E+09 3.41E+08 2.23E+09 
5m 4.52E+08 2.09E+09 9.25E+08 3.69E+08 4.64E+09 
1m 2.22E+08 0.00E+00 1.53E+09 5.28E+08 1.48E+09 
No30m 5.65E+08 1.89E+09 9.53E+08 2.01E+08 8.26E+08 
1 h - Trial 2 
30m 6.65E+08 5.45E+09 4.40E+07 1.95E+08 3.54E+07 
15m 7.41E+08 1.07E+09 2.94E+07 1.56E+08 5.36E+07 
5m 3.61E+08 3.43E+09 4.09E+08 1.12E+09 2.13E+09 
1m 5.33E+08 1.02E+09 0.00E+00 9.02E+06 0.00E+00 
No30m 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
1 h - Trial 3 
30m 3.52E+07 0.00E+00 8.63E+09 2.28E+09 0.00E+00 
15m 6.43E+08 8.20E+07 2.80E+08 1.17E+08 4.47E+07 
5m 2.38E+07 5.31E+07 6.54E+08 0.00E+00 4.85E+09 
No30m 1.23E+09 5.64E+08 0.00E+00 2.89E+08 0.00E+00 
8 h - Trial 1 
30m 0.00E+00 0.00E+00 4.30E+07 0.00E+00 0.00E+00 
15m 2.29E+07 2.07E+10 2.98E+09 5.21E+08 2.25E+09 
5m 2.13E+08 2.79E+09 1.04E+09 2.98E+08 1.75E+09 
1m 9.94E+08 5.64E+07 3.38E+08 2.17E+07 0.00E+00 
No30m 0.00E+00 1.55E+08 1.04E+09 5.20E+08 8.58E+08 
8 h - Trial 2 
30m 2.47E+07 0.00E+00 4.59E+07 2.26E+08 4.12E+08 
15m 2.74E+09 1.52E+09 9.46E+08 1.31E+08 8.46E+07 
5m 2.32E+07 8.04E+08 6.21E+08 1.31E+07 1.34E+09 
1m 0.00E+00 4.31E+09 0.00E+00 1.60E+08 3.27E+09 
No30m 9.89E+08 1.82E+09 4.02E+08 2.61E+08 3.55E+08 
8 h - Trial 3 
30m 4.68E+08 1.02E+09 2.81E+09 2.26E+08 2.88E+09 
15m 3.03E+08 1.70E+10 1.11E+09 3.09E+08 7.53E+08 
5m 2.11E+08 3.42E+09 1.47E+09 3.18E+09 4.02E+08 
1m 4.61E+08 8.69E+09 0.00E+00 0.00E+00 2.13E+09 
No30m 0.00E+00 0.00E+00 0.00E+00 9.47E+08 5.06E+07 
24 h - Trial 1 
30m 0.00E+00 0.00E+00 3.30E+07 8.49E+08 2.17E+09 
15m 2.07E+07 7.32E+08 0.00E+00 0.00E+00 0.00E+00 
5m 0.00E+00 7.32E+07 0.00E+00 0.00E+00 0.00E+00 
1m 2.76E+09 2.98E+09 9.02E+07 1.66E+08 1.35E+09 
No30m 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
24 h - Trial 2 
30m 2.28E+07 0.00E+00 2.54E+10 3.85E+08 1.75E+09 
15m 1.11E+09 5.98E+08 1.25E+09 1.86E+08 4.16E+08 
5m 2.15E+08 1.14E+09 6.77E+07 1.14E+07 3.79E+07 
1m 0.00E+00 0.00E+00 3.52E+07 1.16E+07 7.32E+07 
No30m 2.20E+08 0.00E+00 5.06E+07 1.68E+08 0.00E+00 
24 h - Trial 3 
30m 2.72E+08 1.48E+10 3.41E+08 1.09E+08 2.85E+09 
15m 2.43E+08 9.27E+09 1.47E+09 3.10E+08 1.03E+09 
5m 4.56E+08 6.68E+07 4.81E+08 0.00E+00 1.08E+09 
1m 8.41E+08 2.44E+10 5.98E+08 9.84E+08 3.65E+09 
No30m 2.07E+09 5.27E+08 4.35E+08 3.10E+08 1.96E+09 
 
Table B.2 - Number of MNBs per gram of Tissue for each Condition 
MNBs present in tissues were quantified as outlined in materials and methods and were divided by grams of tissue 
(Table A.2) to normalize values to MNBs per gram of tissue. Incubation time refers to the time post exposure until 
euthanasia. Exposure time refers to the amount of time the tail was dipped into the solution containing BAP-MNBs 
with or without DMSO. 15m refers to 15 min exposure time with 0.1% DMSO. No30m refers to 30 min exposure 





















30m 3.18E+08 2.05E+09 2.90E+09 8.91E+08 7.83E+09 
15m 6.69E+08 9.04E+08 4.80E+08 2.05E+08 7.77E+08 
5m 2.79E+08 1.86E+09 6.63E+08 4.95E+08 3.87E+09 
1m 3.77E+08 5.09E+08 7.65E+08 2.68E+08 7.40E+08 
No30m 5.99E+08 8.19E+08 3.18E+08 1.63E+08 2.75E+08 
8 h 
30m 1.64E+08 3.41E+08 9.67E+08 1.51E+08 1.10E+09 
15m 1.02E+09 1.31E+10 1.68E+09 3.21E+08 1.03E+09 
5m 1.49E+08 2.34E+09 1.04E+09 1.17E+09 1.16E+09 
1m 4.85E+08 4.35E+09 1.13E+08 6.05E+07 1.80E+09 
No30m 3.30E+08 6.57E+08 4.82E+08 5.76E+08 4.21E+08 
24 h 
30m 9.84E+07 4.93E+09 8.59E+09 4.48E+08 2.25E+09 
15m 4.59E+08 3.53E+09 9.08E+08 1.66E+08 4.82E+08 
5m 2.24E+08 4.28E+08 1.83E+08 3.79E+06 3.74E+08 
1m 1.20E+09 9.14E+09 2.41E+08 3.87E+08 1.69E+09 
No30m 7.65E+08 1.76E+08 1.62E+08 1.59E+08 6.52E+08 
 
Table B.3 - Average Number of MNBs per gram of Tissue between Trials 
MNBs/g values from Table A.3 were averaged between the 3 trials for each condition. Incubation time refers to the 
time post exposure until death. Exposure time refers to the amount of time the tail was dipped into the solution 
containing BAP-MNBs with or without DMSO. 15m refers to 15 min exposure time with 0.1% DMSO. No30m 




Figure B.1 - Atto633 Encapsulated BAPCs Visualized in Mice Tails Post Transdermal Exposure 
Images taken 1, 8, or 24 h post 15 min exposure as indicated. The fluorescence is shown as green on the bright-field 
background. All pictures were captured in the same condition in a LSM700 confocal microscope. (A) 1 h incubation 
time post 15 min exposure; (B) 8 h incubation time post 15 min exposure; (C) 24 h incubation time post 15 min 
exposure. For each group N = 1. Bottom arrow indicates the edge of the epidermis, where the arrow’s physical 
location is outside of the tail pointing in. The top arrow in each image is highlighting a hair follicle structure. Scale 








Figure B.2 - Prussian Blue Staining of 
MNBs in Mice Tails 
MNBs were stained with Prussian blue. (A) 15 min 
exposure time, 1 h incubation time. (B) 15 min 
exposure time, 8 h incubation time. (C) 15 min 
exposure time, 24 h incubation time. For each 
group N = 1.  
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Figure C.1 - Copyright Permission for Avila et al. 2015. Molec. Pharm. 12(3): 706-715 
Copyright permissions for Figure 1.2 and Figure 1.3.   
97 
 
Figure C.2 - Copyright Permission for Avila et al. 2018. J. Controlled Release 273: 139-146. 
Copyright permissions for Figure 2.1 C, Figure 2.2, Figure 2.5, Figure A.1, and Figure A.2 as well as related content 
in Chapter 2.   
